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Abstract 
 4 
Sarcopenia and cachexia occur when there is a deficit between the rates of muscle 
protein synthesis and breakdown, such that a negative balance exists. In this thesis, 
the current literature regarding prevalence, pathophysiology and implications of muscle 
wasting is reviewed, and the following hypotheses are tested and discussed: 1) 
thalidomide, taken for 6 weeks, is superior to placebo in terms of weight gain in 
patients with oesophageal cancer and cachexia; 2) administration of high doses of 
insulin overcomes anabolic blunting in older human beings; and 3) the effect of a 
modest increase in blood insulin concentration upon suppression of leg protein 
breakdown is diminished in with ageing.  
The data generated from three separate studies reveals that only the last of these 
hypotheses is likely to be true; nevertheless data obtained from the other two studies 
also adds to the existing literature. Specifically, patients with end-stage oesophageal 
cancer do not tolerate 200 mg per day of thalidomide nor does it carry any benefit in 
terms of acquisition of lean tissue or other control of disease-related symptoms, 
whereas aggressive medical and dietary support results in weight gain, including lean 
body mass, in the same patient group. Healthy volunteer studies using high dose 
insulin to overcome anabolic blunting in ageing were hampered by insufficient plasma 
AA concentrations; however blunted signalling responses remained despite equivocal 
rates of muscle protein turnover. Finally, the last study demonstrates a difference 
between young and older healthy volunteers in proteolytic responses to administration 
of modest doses of insulin.   
This thesis reveals that deficits in protein turnover which occur with ageing are two-fold: 
both blunted anabolism and accelerated insulin-driven catabolism. Whether these 
defects are due to “insulin resistance” of muscle metabolism or other age related 
phenomena is unclear, although attempts to overcome anabolic blunting with 
supraphysiological insulin availability were unsuccessful.  
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Skeletal muscle has a wide spectrum of functions ranging between the control of 
body position to blood glucose homeostasis. Ill-health and ageing deplete muscle 
mass, most noticeably leading to loss of strength, increased fatigueability and a 
decline in body stability, particularly at ankles, knees and hips, and thereby to an 
increased risk of falling and subsequent injuries (Roubenoff 2000; Wolfson et al. 
1995). Severe sarcopenia increases the likelihood of developing a disability by 2-
fold in men and 3-fold in women (Janssen, Heymsfield, & Ross 2002) and doubles 
the odds of dying (Cawthon et al. 2007). The subsequent costs of age-related 
wasting alone have been calculated to be of the order of $18.5 billion in the USA 
(Janssen et al. 2004b), i.e. an excess cost of $900 per individual (at 2003 prices). 
The true cost is likely to be greater still as these figures do not take into account 
the added healthcare costs associated with non-musculo-skeletal diseases in 
wasted individuals. Post-operative hospitalisation and complications, including 
pneumonia, are increased in patients with evidence of muscle wasting (Windsor & 
Hill 1988; Warnold & Lundholm 1984); diminished grip strength, which correlates 
with loss of lean tissue loss (Heimburger et al. 2000), is associated with increased 
mortality due to heart disease, stroke, pneumonia and cancer (Gale et al. 2007; 
Sasaki et al. 2007). Thus preservation of muscle tissue is both an important 
preventative health measure and economic measure affecting the individual and 
society as a whole. A review of published data pertaining to muscle wasting, 
specifically exploring the underlying physiological processes by which muscle is 
maintained and lost, is presented in this thesis. The effects of amino acids (AA), 
and insulin upon muscle turnover in young and older human beings are explored, 
in addition to an evaluation of the role of thalidomide in cancer cachexia.  
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1.1 The role of muscle in health 
The principal functions of skeletal muscle are to enable the body to maintain posture 
and to move, both of which depend upon an adequate mass of appropriately composed 
muscle and a properly functioning motor-control system. However, muscle also has 
many metabolic functions.  
 
Skeletal muscle is probably the most important tissue for insulin-dependent glucose 
disposal in the body (Shulman 2000). The processes of glucose transport, glycogen 
synthesis and glucose oxidation all appear to be vulnerable to deterioration with ageing 
(Krishnan, Evans, & Kirwan 2003; Houmard et al. 1995; Gumbiner et al. 1992) and 
disease (Shulman 2000), resulting in hyperglycaemia and insulin resistance or 
insensitivity. Together with the heart, skeletal muscle accounts for most of the fatty acid 
oxidation in the body which, if diminished or inefficient, is associated with glucose 
intolerance and insulin resistance (Guo 2007). Thus loss of muscle has significant 
implications upon glucose homeostasis. 
 
Muscle also contains 35 % of all total body protein (Cohn et al. 1980), which is 
maintained by a continual process of protein synthesis and breakdown accounting for 
between a quarter and a half of all protein turnover in the body, depending on the state 
of feeding (Tessari et al. 1996; Wagenmakers 1999). Amino acids released during 
protein turnover are used elsewhere in the body for wound healing or, in the cases of 
the amino acid glutamine, (which is mainly synthesized in muscle from glutamate) as a 
fuel for rapidly turning-over cells, including those of the immune system. Glutamine 
also provides a substrate for nucleic acid base synthesis and is a source of ammonia 
for acid-base regulation (Taylor & Curthoys 2004). Branched chain amino acids 
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(BCAA) also function as fuels for cardiac and skeletal muscle (although contributing no 
more than ~15% to the total fuel requirements during exercise (Rennie et al. 2006)). 
Glycogen is also stored in muscle and used locally as an energy source or, after 
glycolysis and conversion to lactate, exported for use by the heart or brain directly and 
for gluconeogenesis to produce glucose. Muscle is also important in the metabolism of 
BCAA (which are toxic if accumulated in the blood) to produce keto acids which are 
themselves used as fuel in a number of tissues and as a substrate for glutamine and 
alanine synthesis, both of which are gluconeogenic precursors.  
 
Finally there is emerging evidence that muscle may have a humeral role, expressing 
interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-15 (IL-15) (Pedersen et al. 
2007). These cytokines act both locally and systemically and could plausibly be 
associated with the reduction in cancer risk associated with increased exercise and 
muscle mass. Thus, maintenance of an adequate skeletal mass is not only vitally 
important for locomotion but also blood sugar control, fat and protein homeostasis and 
immune functioning, to enable longevity and good health.  
 
1.2 Means of measuring muscle mass 
Ideally, the diagnostic criteria for muscle wasting should be based upon knowledge of 
the normal distribution across all relevant ethnic populations of actual muscle mass, 
measured using techniques which are accurate, precise and reproducible – and if 
possible cheap and easily clinically applicable. A major problem is that no existent 
method measures the mass of skeletal muscle cells per se; all use model based 
quantification of a structural component of muscle, or a product of muscle metabolism, 
such as phosphocreatine. The degree of accuracy is model dependent although the 
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best method, magnetic resonance imaging (MRI), is validated against anatomical 
analysis of cadavers and is associated with errors of as little as 2 % (Engstrom et al. 
1991; Mitsiopoulos et al. 1998). The inherent errors of each technique are likely to 
increase with greater degrees of wasting, and to a greater extent in methods validated 
indirectly e.g. impedance.  
 
A further difficulty is that mass of muscle, determined by whatever means, does not 
necessarily predict functional muscle mass. Alterations in muscle fibre components 
(e.g. actin and myosin amounts and isoforms) and myofibre function, or metabolic 
characteristics (e.g. creatine phosphate content or mitochondrial oxidative capacity) are 
not given by any of the imaging modalities in current use. For a true composite picture, 
serial muscle biopsies, metabolic studies and muscle mass estimations are required; 
however recurrent invasive procedures are both costly and deter otherwise enthusiastic 
volunteers, limiting widespread applicability and limiting most studies to a single 
modality.  
 
Most workers use lean body mass (LBM) (or fat free mass – terms often used 
interchangeably as they both reflect all mass which is not bone mineral or non-
essential fat mass (Wang 1992)) as a proxy measure to quantify muscle mass. LBM is 
calculated by subtracting fat and bone mineral mass from total body mass (except 
when measured directly by whole body 40potassium counting) and includes both 
intracellular and extracellular water. In health extracellular water remains relatively 
constant; however in disease states the proportion of interstitial water increases and 
limits the interpretation of changes in LBM. Nevertheless techniques that measure 
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muscle mass directly, i.e. MRI and CT, are limited by their expense or radiation 
exposure.  
 
Notwithstanding financial constraints, MRI is currently the optimal technique, providing 
accurate, sensitive and reproducible values. The technique is safe for both 
investigators and participants and can yield muscle fibre type composition data if 
required (Houmard, Smith, & Jendrasiak 1995). Patient tolerability remains a limitation 
and increasingly individuals cannot be scanned due to implanted devices or clips. 
Conventional MRI incurs a cost of ~£300 per investigation in most NHS 
establishments; however the development of fixed magnet low field (0.2 Tesla) 
scanners means that MRI is becoming accessible to research units (Morse et al. 2005). 
 
A slightly less expensive alternative to collect near gold-standard data, incurring errors 
of up to 6 % (Ross & Janssen 2005), is computerized tomography (CT). Radiation risk 
precludes serial measurements in healthy volunteers; but CT is used to stage and 
monitor disease progression in clinical practice and therefore a wealth of body 
composition data exists that has not been fully exploited. A major limitation is the 
absence of body composition software, so data manipulation remains a manual 
process.    
 
Dual energy X-ray absorptiometry (DEXA) has been developed as an operator friendly 
tool for the assessment of body composition, with very simple and easy to use 
software. It is much cheaper than MRI (~ £50 per investigation), but it is less useful in 
imaging muscle tissue partly because muscle is relatively X-ray transparent and 
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complicated calculations need to be used to “subtract” for bone and fat masses; fluid 
retention also increases LBM but not fat (Humphries et al. 2000) which is of relevance 
when studying disease or treatment related changes in body composition. DEXA has a 
further disadvantage that it cannot be used tomographically i.e. no cross sectional 
images can be produced; only integrated plan views of density of a volume. 
Furthermore the errors for muscle or appendicular lean tissue are greater than for MRI. 
 
Since the 1960s a limited number of specialist research units (approximately 30 
worldwide) have used whole body 40potassium (40K) counting as a measure of LBM 
(Forbes & Hursh 1961). In the human body potassium is an intracellular cation existing 
almost entirely within fat free tissue, thus estimates of total body potassium (TBK) 
correlate directly LBM. Potassium abundance in tissue is readily determined due to the 
presence of its radioactive isotope, 40K, (~0.0118 % of TBK), which is detectable by 
gamma-ray emissions. At one time this technique was considered a “gold-standard” 
(Pierson, Lin, & Phillips 1974), providing a direct measure of LBM without the need to 
fast or exposure to radiation, in a patient-friendly environment. The availability of 
specialized facilities remains a major limitation of TBK counting, as is the lack of 
regional body composition data. 
 
An alternative, older, technique (which also lacks regional body composition data) is 
the use of “heavy” water to quantify total body water (Schloerb et al. 1950; Lifson N, 
Gordon GB, & McClintock R 1955). Either deuterium oxide (D2O) or 18-oxygen water 
(H218O) is used as a tracer and administered after a baseline fluid sample is collected. 
Isotope dilution is measured in saliva, blood or urine after an equilibration period, as 
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water is distributed throughout all parts of the body except adipose tissue. Total body 
water can be used to estimate LBM using the simple equation: 
 
LBM = Total Body Water / 0.72 
 
Both tracers overestimate total body water as a result of binding to non-exchangeable 
sites, such as acidic amino acids, thus a correction factor is applied to minimise error.  
Albeit safe, easy to perform, and relatively accurate, use of this technique is limited due 
to its expense - both the isotope and analysis costs are high. 
 
An inexpensive alternative is bioelectrical impedance analysis (BIA). This technique 
uses the differential electrical impedance of fat and lean tissue to estimate LBM. 
Development of multiple frequency algorithms have improved the validity of BIA 
(Rubiano, Nunez, & Heymsfield 2000), but substantially greater imprecision and 
inaccuracy persist with this method, particularly in the presence of electrolyte or fluid 
depletion, in comparison with other methods. Nevertheless BIA is cheap, portable and 
easily employed in epidemiological studies by relatively untrained staff.  
 
These advantages are also shared by techniques measuring muscle metabolites in 
urine. Here muscle mass is estimated based on the excretion of creatinine or 3-methyl 
histidine (on the assumption that they are derived from muscle). A high degree of 
subject compliance is needed for both adherence to a strict meat free diet and 
complete 24 h urine collection. Accuracy of 3-methyl histidine as a marker of muscle 
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mass is a problem when total body mass is low, because of the proportionally greater 
contribution of 3-methyl histidine produced from the skin and smooth muscle in the gut 
(Afting et al. 1981; Rennie & Millward 1983). Furthermore, creatinine, when used as a 
measure of muscle mass in older adults, gives higher values than DEXA or deuterated 
water dilution (Proctor et al. 1999). Novel data demonstrates a tighter correlation 
between plasma myoglobin and the cross-sectional area of the quadriceps or body cell 
mass, as quantified by MRI and BIA respectively, when compared to creatinine values 
(Weber et al. 2007). The ease of measurement and reproducibility of this latest method 
suggest it may be utilized more widely in the future.   
 
Despite the variety of techniques available to measure body composition, only 
relatively small numbers of the population (especially of sex and ethnic specific 
subgroups) have been examined by any method and even fewer have been measured 
using “near gold standard” methods such as MRI or CT. It has been calculated that in 
order to construct percentile charts of muscle mass at 5 y intervals that would be 
accurate and clinically useful, about 300 - 400 people of any particular group at each 5 
y point would be needed (Guo et al. 2000). The biggest sample size of healthy adults 
examined so far with a reliable method is of the order of 1800 older adults with a mean 
age of 74 years (Goodpaster et al. 2006); very little data is published regarding the 
body composition changes associated with disease.  
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Table 1.1  Comparison of body composition measurement techniques 
 Benefits Limitations 
MRI 
Magnetic 
Resonance 
Imaging 
• Gold-standard (cadaveric anatomical validation) for accuracy 
and precision 
• No radiation exposure 
• Direct measurement of skeletal muscle mass is possible  
• Low field MRI (for limbs only) is near perfect, much less 
expensive and easy to operate.  
• Expensive (~£300 per scan) due to high initial capital 
costs (~£200,000), maintenance and service costs  
• Highly trained technical staff required and no standard 
software for body composition analysis 
• Subject acceptability - noise and claustrophobia. 
• Excludes subjects with implanted metal work 
DEXA  
Dual Emission 
X-Ray 
Absorptiometry 
• Reasonable precision and accuracy (within 1.5 and 4 % 
respectively for LBM)  
• Particularly useful for longitudinal change  
• Less expensive than MRI and CT (~£50 per scan) 
• Standard software for body composition  analysis available  
• Minimal radiation exposure  
• Minimal operator training required. 
• High initial capital costs (£60 000)  
• LBM is determined indirectly based on adipose and bone 
mass and thus is affected by hydration status and 
intramyocellular fat.  
• Skeletal muscle mass is not determined 
• No tomographic (i.e. cross sectional) information 
40K -whole 
body 
potassium 
counting 
• Good precision and accuracy for LBM and skeletal mass, 
validated against MRI and cadaveric analysis  
• Direct quantification of LBM  
• No radiation exposure (40K occurs naturally within the body)  
• Subject friendly - fasting is not required  
• Dedicated facilities required  
• Skeletal muscle mass is estimated using the ratio of total 
body potassium content to that in skeletal muscle - a 
relatively stable index in healthy adults, but not fully 
validated in wasting disorders  
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CT 
Computer 
Tomography 
• Good  precision and accuracy  
• Direct measurement of anatomical skeletal muscle mass is 
possible  
• Routinely used in clinical practice. 
• Substantial radiation exposure 
• Expensive but running costs less than MRI 
• Highly trained technical staff required and no standard 
software for body composition analysis 
Urinary 
Excretion of 3- 
Methylhistidine 
(3-MH) 
• Inexpensive 
• Home urine collections enable recruitment of housebound 
subjects 
• In healthy subjects, predominantly measures muscle mass  
• Relies upon subject compliance to meat-free diet for ≥ 72 
h and complete 24 h urine collection 
• Insensitive measure (CV ~ 5 % with good compliance) 
• Inaccuracies amplified when body mass low (greater 
contribution of 3-MH from gut and skin) 
BIA 
Bioelectrical 
impedance 
analysis  
• No radiation exposure  
• Portable 
• Inexpensive equipment  
• Minimal operator training required 
• Precision and accuracy is poor 
• Very dependent upon hydration status  
• Pre-test exercise affects measurements 
• LBM overestimation in obesity 
• Few validations in ageing or disease populations 
Total body 
water by 
isotope dilution 
- deuterium 
oxide (D2O) or 
heavy water 
(H218O) 
• Accuracy and precision of total body water estimates are 
reasonable (< 1 % and < 4 % respectively).  
• No radiation 
 
• Expensive (isotope and analysis costs) 
• LBM is an estimate based on a constant distribution of 
water in LBM  
• H218O overestimates total body water by ~1 %, as it can 
bind to non-exchangeable sites such as acidic amino 
acids, and D2O by 5 % as take up into lipid. 
• Typical protocols take up to 6 h for complete equilibrium.  
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1.3 Maintenance of muscle mass 
1.3.1 Control of muscle protein turnover 
Although the pathophysiology of muscle wasting, whether due to ageing or disease, or 
a combination of both processes, is complex and only partly understood, it is clear that 
changes in muscle protein turnover are required for alterations in muscle mass to 
occur. Many hormonal, metabolic and physical stimuli influence muscle protein 
synthesis (MPS) and muscle protein breakdown (MPB) to generate a net balance; a 
positive net balance results in muscle growth whereas muscle is lost if the balance is 
negative.  For the most part MPS governs gradual changes in muscle mass (facilitative 
role) and MPB adapts in response to preserve tissue (adaptive role) (Rennie et al. 
1983). The reverse is true of conditions resulting in rapid muscle loss, such as burns, 
trauma and sepsis; in these situations net muscle loss occurs due to accelerated MPB 
albeit with increased MPS, but to a lesser degree (Rennie 1985) (Figure 1.1).  
 
In health, there is a diurnal change in muscle turnover. In the postabsorptive state (PA; 
i.e. following a 12 h fast) MPB exceeds MPS. During absorptive periods both rates 
increase, albeit MPS increases greater than MPB. Typical rates of muscle synthesis,  
after an overnight fast, expressed as tissue fractional synthetic rate (FSR; i.e. rate of 
protein increase proportional to the total muscle protein mass) vary between 0.04 and 
0.08 %.h-1 for mixed muscle protein depending upon the stable isotope tracer, the 
precursor estimate, analysis techniques and theoretical model used (Smith, Villareal, & 
Mittendorfer 2007); measurements taken with leucine are ~20 % greater than that 
using phenylalanine, regardless of the position of the labelled element.  Typical values 
for mixed muscle, sarcoplasmic and myofibrillar protein synthesis in the PA state, 
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quantified using [13C]leucine and methodology consistent with that presented in this 
thesis, are 0.05, 0.06 and 0.03 %.h-1, respectively (Cuthbertson et al. 2005).  
 
 
 
 
 
Figure 1.1  Representative values of skeletal muscle fractional synthetic rate (FSR) 
averaged over a 24 h period, assuming normal dietary intake, in healthy individuals and 
those with slow and rapid wasting conditions.  
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Influence of amino acids upon muscle turnover 
In health and disease the balance of muscle protein turnover is controlled by a host of 
anabolic and catabolic stimuli, of which the most powerful anabolic agents are AA 
(Bennet et al. 1989; Rennie et al. 1982), specifically the essential AA (EAA) (Smith et 
al. 1992; Tipton et al. 1999; Volpi et al. 2003). Indeed there is some evidence 
suggesting that BCAA, particularly leucine, are sufficient to stimulate MPS 
independently, regardless of the availability of other AA (Smith et al. 1992; Smith et al. 
1998; Kimball et al. 1999). Nevertheless all EAA are required to sustain muscle growth: 
intracellular EAA fall by as much as 50 % over a 90 minute period in the absence of 
continued provision. 
 
The anabolic effect of EAA upon FSR correlates with extracellular availability (Bohé et 
al. 2003), although there appears to be a latency period of ~30 min before synthesis is 
increased (Bohé et al. 2001). A 2-3 fold increase in MPS results from a 50 % rise in 
EAA availability (Smith & Rennie 1996), but MPS returns to basal levels after ~2.5 h 
despite continued EAA availability (Bohé et al. 2001).  The length of the ensuing 
refractory period, during which EAA administration does not result in accelerated MPS, 
is unknown. However this 2.5 h anabolic window is in keeping with the physiological 
changes in AA availability following a meal, in which AA typically return to basal levels 
by 3 h (Bergström, Furst, & Vinnars 1990).  
 
The anabolic effect of AA appears restricted to synthesis; increased AA availability has 
no effect upon MPB (Biolo et al. 1997; Volpi et al. 1999; Volpi et al. 2003; Bennet et al. 
1990b). Reports of increased MPB following AA administration have been published 
but the authors were unable to demonstrate a concomitant increase in MPS suggesting 
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flaws in the data (Nair, Schwartz, & Welle 1992; Louard, Barrett, & Gelfand 1990). 
Other workers have suggested that AA can suppress proteolysis but their data was 
generated by administering both AA and glucose without insulin clamping and thus the 
observed effect upon proteolysis is better explained by the accompanying insulin rise 
(Volpi et al. 2000). The effects of insulin upon proteolysis are discussed subsequently. 
 
Influence of exercise upon muscle turnover  
After AA, exercise is probably the most important anabolic stimulus for skeletal MPS. 
High-force contractions (resistance exercise) increase MPS by 50 – 100 % of basal 
rates, albeit with a simultaneous increase (~50 %) in MPB. Less is known about the 
effects of endurance exercise upon muscle turnover; walking (Carraro et al. 1990) and 
swimming (Tipton et al. 1996) increase MPS by 100 and 60 % respectively but there 
are no data on MPB. The amplitude of response to a bout of exercise appears to be 
influenced by duration, intensity and whether the muscle has been trained in that 
particular type of exercise. Indeed conflicting time course data is best explained by the 
variable study conditions and differences between human beings. Heavily trained 
muscle differs from that which is untrained in its response to resistance exercise (but 
not endurance exercise) in that FSR does not appear to increase (Tipton et al. 1996; 
Roy et al. 1997). Furthermore, the rate of anabolism is profoundly influenced by the 
availability of AA during and after exercise, although the time course of maximal 
anabolic responses with feeding is not fully understood. In the postabsorptive state 
maximal synthesis appears to occur between 1 and 2 h after resistance exercise 
(Kumar et al. 2009); however this may not hold true when exercise is accompanied by 
feeding. 
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FSR appears to be reduced during muscle contractions (Carraro et al. 1990; Dreyer et 
al. 2006) in keeping with whole body (Rennie et al. 1981) and rodent (Bylund-Fellenius 
et al. 1984) data, at least in the postabsorptive state. Recent data (Fujita et al. 2009a) 
suggests that feeding with a mix of AA and carbohydrates 1 h before RE attenuates the 
reduction in FSR; i.e. synthesis increased in the first hour with feeding but dropped 
during the exercise bout to rates similar to unexercised fasted muscle, whereas FSR 
fell below this rate during exercise in unfed control subjects. Signalling work also 
confirms that the phosphorylation of the eukaryotic elongation factor 2 (eEF2) at Thr56 
(which slows protein synthesis) is increased by 5 – 7 fold within 1 min of exercise 
commencing (Rose et al. 2005). Conflicting data, collected during short bouts of 
exercise (~45 min) suggest either a rise (Sheffield-Moore et al. 2004) or no change in 
FSR (Durham et al. 2004); however, the analytical technique used in both studies, gas 
chromatography-mass spectrometry (GC-MS), is not sufficiently sensitive to accurately 
detect small changes in tracer enrichment within the muscle as occur over periods of 
less than 90 min.  
 
Immediately after an exercise bout there is a “latency period” of variable duration, 
before accelerated synthesis is switched on and MPS rates increase by ~100 % 
(Chesley et al. 1992; Biolo et al. 1995). As the basal rate of MPB is greater than that of 
MPS when studied under PA conditions, and a simutaneous increase in MPB occurs 
(~50 %) (Biolo et al. 1995), net balance remains neutral (Figure 1.2). Thus, absorptive 
conditions are required to maximise the anabolic benefits of exercise. Amino acids and 
exercise synergistically increase MPS by up to ~2-3 times basal values (Louis et al. 
2003; Cuthbertson et al. 2006) without a concurrent increase in MPB  (Biolo et al. 
1997) (possibly due to the rise in blood insulin concentrations), resulting in a positive 
net balance and accretion of muscle. 
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Figure 1.2  Muscle protein synthesis (MPS) and breakdown (MPB) rates during post-
absorptive (PA) unexercised conditions, and in response to exercise (Ex) with and 
without feeding.  Data are approximate and generated from the literature. 
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The state of enhanced anabolism following exercise lasts in the order of ~48 h (Phillips 
et al. 1997); however the latency period is less well defined. Some authors report 
maximal anabolic responses within 2 (Kumar et al. 2009), 3 (Louis et al. 2003) or 4 h 
(Biolo et al. 1997; Chesley et al. 1992; Tang et al. 2008), whereas others describe no 
synthetic response 3 h after extremely strenuous exercise, but maximal responses at 6 
and 24 h (Cuthbertson et al. 2006), suggesting that the duration of the latency state 
may be related to the intensity of the exercise or availability of AA. Indeed data from 
habitually trained individuals, referred to earlier, indicated no change in FSR over 5 
(Tipton et al. 1996) or 10 h (Roy et al. 1997) after a significant bout of resistance 
exercise (65 % and 85 % of 1 repetition maximum respectively), possibly due to a 
prolonged latency period; measurements were not made at latter time points to confirm 
this hypothesis.  
 
Data regarding the optimum timing of AA feeding after exercise has been inconsistent, 
possibly due to marked differences between exercise protocols, the route and choice of 
nutrients, the degree of habitual activity of participants and activity levels immediately 
preceding the study. Nevertheless, early feeding after exercise appears to increase the 
maximal rate of protein synthesis (Levenhagen et al. 2001) and recently published data 
demonstrates a clear dose-response effect (up to a maximum dose of ~20 g of protein) 
(Moore et al. 2009). Robust DEXA data from two studies, each collected over a 12 w 
training programme, confirm that immediate protein supplementation after exercise 
results in greater accretion of LBM than feeding delayed by 2h or more (Hartman et al. 
2007; Esmarck et al. 2001).  
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Influence of insulin upon muscle turnover 
Insulin is a powerful anabolic stimulus, either accompanying nutrients, in isolation 
under experimental clamp conditions or after resistance exercise. Insulin promotes 
muscle “growth” primarily by inhibition of proteolysis and does so in a dose-dependent 
fashion (Chow et al. 2006; Moller-Loswick et al. 1994; Petrides, Luzi, & DeFronzo 
1994; Louard et al. 1992; Arfvidsson et al. 1991; Fryburg et al. 1990; Flakoll et al. 1989; 
Gelfand & Barrett 1987; Tessari et al. 1986); although the maximal inhibitory dose is 
less clear. Gelfand and colleagues propose that maximal inhibition of proteolysis 
occurs at modest plasma insulin concentrations (~ 30 µIU.ml-1) (Louard et al. 1992; 
Gelfand & Barrett 1987; Pozefsky et al. 1969), whereas other workers suggest maximal 
inhibition occurs at concentrations exceeding the physiological range (upwards of 400 
µIU.ml-1) providing that AA availability is maintained at postabsorptive concentrations 
(Flakoll et al. 1989; Tessari et al. 1986; Fukagawa et al. 1985).   
 
Whether increased insulin concentrations stimulate MPS is controversial. Biolo and 
colleagues report unequivocally that MPS, as determined by both tracer incorporation 
and A-V balance, is stimulated by insulin even in the presence of relative 
hypoaminoacidaemia (Biolo, Fleming, & Wolfe 1995; Biolo et al. 1999). Other workers 
report a positive net balance when studying leucine and phenylalanine kinetics across 
the arm in response to hyperinsulinaemia; however phenylalanine kinetics indicate that 
anabolism is the result of reduced MPB, whereas leucine kinetics point towards 
enhanced MPS (Newman et al. 1994). More robust data demonstrates that human 
beings are almost insensitive to insulin in terms of stimulation of protein synthesis at 
PA concentrations of AA (Chow et al. 2006; Moller-Loswick et al. 1994; Gelfand & 
Barrett 1987) and that insulin has no summative effect upon EAA driven MPS 
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(Greenhaff et al. 2008). Nevertheless, insulin reduces leucine oxidation (Ang et al. 
2000), increases blood flow to the tissue (Fujita et al. 2006; Biolo et al. 1999; 
Arfvidsson et al. 1991) and may have a direct effect upon AA transport into the cell 
(Biolo, Fleming, & Wolfe 1995). Thus MPS may be enhanced under certain 
experimental conditions and not others due to variations in intracellular AA availability 
in response to hyperinsulinaemia, rather than a direct effect of insulin. Furthermore, 
some authors have suggested that low dose insulin may be a requirement for 
stimulation of MPS in response to hyperaminoacidaemia, a so called “permissive” role 
(Rennie 2005). Testing this hypothesis would require measurement of MPS in 
response to feeding with a full pancreatic clamp without exogenous replacement of 
insulin.  No such study has been conducted to date. 
 
1.3.2 Cellular control of protein synthesis 
The rate of MPS is determined at the molecular level by the production and 
phosphorylation of eukaryotic initiation factors (eIF) which control the rate of protein 
translation. Translation, the process by which messenger ribonucleic acid (mRNA) is 
used to generate polypeptides, occurs within the cytoplasm in 3 stages: initiation, 
elongation and termination. The binding of eIF2.GTP.Met-tRNAimet to the 40S ribosome 
forms the first step of initiation and is governed by the availability of eIF2.GTP (GTP: 
Guanosine triphosphate) complex.  eIF2.GDP (GDP: Guanosine diphosphate) is in 
abundant supply; however phosphorylation to eIF2.GTP is catalyzed by eIF2B, an 
enzyme which is inhibited by eIF2α and glycogen synthase kinase (GSK) 3ß. Low AA 
concentrations and Protein Kinase B (PKB; also called Akt) inactivation promote eIF2α 
and GSK3ß activity.  When AA supply is adequate eIF2.GTP.Met-tRNAimet binding to 
the 40S ribosome creates the 43S pre-initiation complex. 
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mRNA binding to the 43S pre-initiation complex requires an assembly of 3 initiation 
factors, eIF4E, eIF4G and eIF4A, the assembly of which is termed eIF4F. Each 
component of eIF4F has an essential role: eIF4E binds to the mRNA cap structure, 
eIF4A unwinds secondary structures of the mRNA and eIF4G serves as a scaffold 
protein binding eIF4A, eIF4E and mRNA to the ribosome (Pain 1996). Here eIF4E is 
the rate limiting factor (Lang et al. 2003) and is regulated by eIF4E-binding protein 1 
(4E-BP1). Increased EAA availability enhances 4E-BP1 hyperphosphorylation, 
rendering it inactive as an inhibitory binding protein and enabling eIF4E to enter the 
eIF4F complex. mRNA binding to the ribosome precipitates release of eIF4F and 
eIF2.GDP for recycling, leaving the active 80S initiation complex. 
 
Once mRNA binds to the 80S ribosome, AA-charged transfer RNA (tRNA) are able to 
commence peptide formation. Transfer RNA are short nucleotide chains which 
selectively bind free AA to an anticodon at the 3’ end. In the same way that three 
nucleotide bases form a codon within mRNA, forming a template for AA linkage, the 
anticodon consists of the opposite bases and dictates the AA specificity of each tRNA 
molecule. During elongation tRNA bound AA (aminoacyl-tRNA) are aligned and 
bonded together, in accordance with the mRNA code, to form a peptide. This 
elongation process requires a significant amount of metabolic energy and is aided by 
eukaryotic elongation factors (eEF) -1 and -2. eEF-1 facilitates aminoacyl-tRNA binding 
to the ribosome, whereas eEF2 is involved with movement of the peptidyl-tRNA 
through the ribosome (Proud 1994). eEF2 kinase, which phosphorylates and 
inactivates eEF2 appears to be negatively regulated by ribosomal protein S6 kinases 
(P70S6K), thus increased intracellular AA may also enhance elongation through 
mammalian target of rapamycin (mTOR) stimulation of P70S6K (Wang et al. 2001).   
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Stop codons within mRNA (UAA, UAG and UGA) are not recognized by tRNA and 
prevent further elongation, resulting in termination. Once this has occurred releasing 
factors detach the polypeptide chain from the ribosome whereupon post-translational 
modifications occur, including folding of the polypeptide into its tertiary protein 
structure.  
 
1.3.3 Amino acid and insulin effects upon protein synthesis  
The intracellular signalling pathways by which AA control protein synthesis and 
breakdown are predominantly centred around mTOR and general control non-
depressing kinase 2 (GCN2);  whereas insulin control of protein metabolism - both 
facilitation of AA signalling and inhibition of breakdown – is governed by the activation 
of the PKB pathway (Figure 1.3). 
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Figure 1.3  Interplay of AA and insulin signalling through protein kinase B and 
mammalian target of rapamycin. Inhibition is indicated by blunt ended lines. 
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Mammalian target of rapamycin (mTOR) 
mTOR is a high molecular weight protein kinase which is particularly sensitive to the 
availability of AA, glucose and ATP (adenosine triphosphate) (Kim et al. 2003). It 
includes a 20 tandem HEAT (Huntingtin, eIF3, a subunit of protein phosphatase 2A, 
TOR) repeat sequence at the N terminus and a kinase domain at the C terminus. This 
kinase domain has structural similarity to the catalytic domain of phosphatidylinositol 3-
kinase (PI3K) (which is involved in the production of phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) and PKB activation) and is responsible for the phosphorylation of 
4E-BP1 and P70S6K (Hay & Sonenberg 2004).  
 
Two stabilizing proteins facilitate the kinase activity of mTOR. The first, Raptor 
(Regulatory associated protein of TOR), binds avidly to the HEAT domains on mTOR 
and more weakly to the kinase domain; Raptor also binds directly to 4E-BP1 and 
P70S6K, facilitating phosphorylation (Kim et al. 2002a). The second stabilizing protein, 
G protein ß-subunit-like protein (GßL), associates primarily with the kinase domain on 
mTOR, both enhancing its kinase activity and its ability to sense nutrients and recruit 
P70S6K and 4E-BP1 (Kim et al. 2003). Further AA sensing and signalling capabilities 
of the Raptor-mTOR-GßL complex result through its interaction with ras homologue 
enriched in brain (Rheb) and the tuberous sclerosis complexes (TSC-1 and TSC-2) 
(Bolster, Jefferson, & Kimball 2004; Gao et al. 2002; Pan et al. 2004; Saucedo et al. 
2003). 
 
The Raptor-mTOR-GßL complex, when fully activated by AA enhances protein 
translation by phosphorylation of p70S6K and 4E-BP1. Phosphorylation of 4E-BP1 at 
Thr37 and Thr46 by mTOR appears to have a priming function, allowing an additional 
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unknown protein kinase to phosphorylate 4E-BP1 at Ser65 and Thr70. In this 
hyperphosphorylated state 4E-BP1 dissociates from eIF4E, allowing eIF4E-eIF4G 
binding. P70S6K is also hyperphosphorylated in its active state; mTOR phosphorylation 
at Thr389 appears to prime this process for subsequent phosphorylation by 3-
Phosphoinositide-dependent kinase-1 and-2 (PDK) amongst other kinases. 
Hyperphosphorylation of P70S6K enhances translation of a specific class of mRNAs 
that contain a 5’-terminal oligopyrimidine structure. Proteins encoded by these mRNAs 
include ribosomal proteins and translational elongation factors, hence cellular protein 
synthetic capacity is enhanced as a result of AA signalling through the Raptor-mTOR-
GßL complex (Kimball, Farrell, & Jefferson 2002).  
 
General control non-depressing kinase 2 (GCN2) signalling 
In contrast to mTOR, which is activated in the presence AA, GCN2 senses and signals 
in response to AA deprivation. Under these conditions, uncharged tRNA (i.e. tRNA 
without bound amino acid) activates GCN2 resulting in phosphorylation of eIF-2α at 
Ser51 (Dong et al. 2000; Sood et al. 2000). In the phosphorylated state, eIF-2α inhibits 
eIF2B and subsequent formation of eIF2.GTP.Met-tRNAimet which is required for first 
stage of translation initiation; furthermore, eIF-2α phosphorylation enhances translation 
of genes encoding for GCN4, a transcriptional activator of over 40 genes which code 
for AA biosynthetic enzymes. Thus the AA-deprived cell is able to down-grade protein 
synthesis, and expresses genes which encode for novel AA synthesis (Hinnebusch 
1997).  
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1.3.4 Role of proteolytic systems 
The degradation of proteins is tightly controlled by at least 5 different proteolytic 
systems. These systems include lysosomal protein degradation (cathepsins), calpains, 
apoptotic proteases (caspases), matrix metalloproteinases and the ubiquitin 
proteasome pathway (Ventadour & Attaix 2006). The specific role of each of these 
systems in muscle protein breakdown is not completely understood, nor is it known 
whether up-regulation of different systems plays a role in muscle atrophy of different 
aetiologies.  However, workers suggest that a sequential combination of two proteolytic 
pathways occur in atrophy states, involving either calpains or caspase-3 prior to 
ubiquitin degradation (Lecker, Goldberg, & Mitch 2006; Hasselgren & Fischer 2001; 
Jackman & Kandarian 2004; Bartoli & Richard 2005).  
 
Three different calpains are in abundant supply within the muscle tissue, calpain-1 (µ 
calpain), calpain-2 (m calpain) and calpain-3 (p94); their activity is governed by 
intracellular calcium concentrations, the abundance calpastatin (an inhibitory protein) 
and removal of the N-terminus (whether by autolysis, phosphorylation or association 
with the plasma membrane).  Thus measurement of calpain activity is not a 
straightforward process. Nevertheless calpain-1 and -2 are thought to be involved in 
dissociation of the myofiloments from the z disc to enable subsequent ubiquitination. 
Calpain-1 and-2 may also impair regeneration of the myofibril, by amongst other 
mechanisms, inhibiting satellite cell regeneration. The role of calpain-3 is less clear, 
indeed there is some suggestion that calpain-3 inhibits muscle proteolysis (Bartoli & 
Richard 2005). 
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The caspases, specifically caspase-3, provide an alternative system for initiation of 
myofibril degradation prior to ubiquitinization. Caspase-3 cleaves actinomyosin and in 
doing so produces a characteristic 14 kDa fragment of actin, which can be quantified 
as a marker of caspase-3 activity (Du et al. 2004).   
 
The fragments of contractile proteins generated by either calpains or caspases are 
further degraded by the 26 S proteosome after tagging by ubiquitin proteins; it is this 
multi-step tagging process that ensures selectivity. Before tagging can occur, ubiquitin, 
a small protein co-factor, is activated by an ATP-dependent enzyme, E1. Upon 
activation, ubiquitin is transferred by E1 to a carrier protein, E2, which enables one of a 
family of ubiquitin-protein ligases (E3 ligases) to couple ubiquitin to the target protein. 
This process is repeated so that a chain of five or more ubiquitins attach to the 
substrate protein, targeting it for proteolysis by the proteasome. Specificity in this 
system is derived from the E2 carrier proteins and E3 ligases: specific E2-E3 pairings 
are required for ubiquitinization of each target protein (Mitch & Goldberg 1996).  
 
Animal work has identified two E3 ligases which are up-regulated in muscle atrophy 
states: Muscle RING Finger 1 (MuRF1) and Muscle Atrophy F-box (MAFbx; also known 
as atrogin-1). MuRF1 and MAFbx are ordinarily expressed in human cardiac and 
skeletal muscle, but expression is enhanced in a variety of rat atrophy models, 
including denervation, immobilization, unweighting, and glucocorticoid induced muscle 
wasting (Bodine et al. 2001). Observations in human beings with wasting disorders 
confirm increased proteosome expression following head injury (Mansoor et al. 1996), 
sepsis (Tiao et al. 1997), cancer (Williams et al. 1999) and AIDS (Llovera et al. 1998). 
Indeed, in cancer patients, expression of ubiquitin mRNA and 20 S proteosome 
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subunits were increased 2-3 fold even prior to the onset of overt muscle wasting 
(Williams et al. 1999).  
 
Control of MuRF1 and MAFbx expression is governed by the Forkhead box Other 
(FOXO) family of transcription factors. Four mammalian isoforms have been identified 
to date: FOXO-1, FOXO-3a, FOXO-4 and FOXO-6 (Nader 2005). All four isoforms are 
involved in metabolic signalling, but specific functions of each are not clearly defined. 
Unphosphorylated, and thus active, FOXOs are located predominantly within the 
nucleus, bound to DNA, whereas phosphorylation by PKB results in nuclear exclusion.  
Re-activation of FOXOs by dephosphorylation and nuclear localization results from 
inactivation of PKB, thus providing a second theoretical mechanism by which insulin 
suppresses proteolysis. Nevertheless, the inhibitor of nuclear factor kappa B kinase 
(IKK), c-Jun-N-terminal kinase (JNK) and proteins associated with glucose metabolism 
have also been shown to alter FOXO activity (Barthel, Schmoll, & Unterman 2005).  
 
Lysosomal proteolysis is driven by the cathepsins, of which cathepsin L is involved in 
breakdown of most myofibrillar proteins. Rat models of atrophy due to sepsis, cancer, 
glucocorticoids and disuse have been associated with over expression of cathepsin L 
(Deval et al. 2001; Taillandier et al. 1996); however its role in atrophy is not entirely 
clear. Cathepsin inhibition studies have failed to show a reduction in protein breakdown 
(Bechet et al. 2005) and as with other proteolytic enzymes, quantification of cathepsin 
mRNA does not directly correlate with lysosomal activity.  
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Understanding of intracellular signalling pathways which control muscle proteolysis is 
extremely limited as data is scarce, particular that collected in human beings. Both 
anabolic and catabolic stimuli are believed to regulate the ubiquitin-proteosome 
system, but the signalling pathways which control initiation of MPB, by either calpain or 
caspase-3 degradation of the myofibrillar apparatus, are unknown (Ventadour & Attaix 
2006; Glass 2005).   
 
1.4 Determinants of muscle loss 
Involuntary loss of muscle tissue results from three separate processes: starvation, 
sarcopenia and cachexia. Starvation occurs in health, is reversed by the re-introduction 
of a normal diet and is caused entirely by nutrient deprivation (Thomas 2007). 
Sarcopenia and cachexia, however, do not readily respond to feeding and are more 
difficult to define. The term sarcopenia was originally coined by Rosenberg to describe 
age-related loss of muscle tissue (Rosenberg 1997), although it has been largely used 
as a generic term for the involuntary loss of muscle with relative preservation of body 
weight, regardless of the underlying aetiology. In the context of this thesis, the term 
sarcopenia will refer purely to loss of muscle tissue due to ageing against a 
background of normal health. In contrast, cachexia is disease-related, is classically 
associated with other symptoms and appears to be a more rapid process. Sarcopenia 
and cachexia are likely to be related entities existing at two different ends of the same 
spectrum; with severe cachexia at one end and early sarcopenia at the other; 
intermittent illnesses accelerate sarcopenia, and cachexia is more common in the 
elderly.  
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1.5 Starvation  
There are no specialized cells that store protein for times of nutrient deprivation but 
muscle protein fulfils the requirement to supply AA during the diurnal cycle and longer 
periods of fasting. In short-term starvation (less than three days), proteolysis is up-
regulated in all tissues (except the brain and reproductive organs) which results in 
mobilization of AA for glucose production and protein synthesis. Proteolysis provides 
the substrate for gluconeogenesis maintaining adequate cerebral blood glucose 
concentrations after hepatic glycogen stores are depleted but before the brain has fully 
adapted to using ketone bodies for fuel. During long-term starvation lipolysis of adipose 
tissue becomes the predominant source of energy and proteolysis is suppressed, thus 
reducing the loss of muscle mass during prolonged nutrient depletion. It is thought that 
the high concentrations of ketone bodies – acetone, acetoacetate and ß-
hydroxybutyrate, produced as a result of acetyl-CoA accumulation within mitochondria 
– are responsible for the suppression of proteolysis (Finn & Dice 2006).   
 
1.6 Sarcopenia  
Sarcopenia seems to be an inevitable consequence of ageing and affects both sexes 
and all races although not necessarily to the same extent. Like most multifactorial 
physiological and pathophysiological processes, it is the result of both genetic and 
environmental influences.  
 
1.6.1 Defining sarcopenia  
All of the current definitions of sarcopenia require a comparison of LBM or skeletal 
muscle mass of the subject under consideration with those of height-and-weight 
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matched young adults. Some workers take two standard deviations below the mean as 
defining significant sarcopenia (Gallagher et al. 1997; Baumgartner et al. 1998). This 
results in estimates of prevalence of 13 - 24 % for men and women aged 65 - 70 y and 
greater than 50 % in those aged more than 80 years. Others (Janssen et al. 2004a) 
use assigned thresholds, for both sexes, in relation to the so called skeletal mass index 
ratio  i.e. LBM per height squared, a modification of body mass index (BMI). Values of 
5.75 kg.m-2 for women and 8.5 kg.m-2 for men were identified as thresholds for 
increased risk of disability using epidemiological data. More recently the muscle mass 
of the limbs, i.e. appendicular lean tissue mass (ALBM) (Kim et al. 2002b), has been 
used in relation to height squared (or more rationally to height alone, since this 
effectively removes height as a variable in the final quotient) to produce an index which 
is clinically useful.  
 
1.6.2 Rate of muscle loss with ageing 
There is broad agreement between authors who have conducted cross-sectional and 
longitudinal studies that diminution of muscle mass and function has already started in 
the third decade of life, with the process accelerating markedly by the fifth decade 
(Larsson, Grimby, & Karlsson 1979; Melton, III et al. 2000; Marcell 2003; Janssen et al. 
2004a). However, the rate of decline is not clearly defined; a variety of authors 
interpreting cross-sectional data have obtained rates varying by an order of magnitude. 
There is some consensus that the period of the fastest decline is from 60 y onwards at 
~0.5 - 2 % per year, depending upon the anatomical location and fibre type 
composition of the muscle (Frontera et al. 2000; Sehl & Yates 2001; Hughes et al. 
2002; Visser et al. 2003; Goodpaster et al. 2006).   
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Losses of strength and power are reportedly up to three-fold greater than that of mass 
(Goodpaster et al. 2006), although there remains great variability between data. Large 
longitudinal cohorts, including one of over 8,000 participants studied over an average 
of 27 y, suggest an average decline of 1 - 2 % per annum in isometric strength (Jubrias 
et al. 1997; Rantanen et al. 1998; Hughes et al. 2001).  Racial differences were 
observed in the Health ABC cohort (Goodpaster et al. 2006) in which over a third of 
participants were black; African Americans lost 28 % more strength than their 
Caucasian counterparts. These participants were assessed identically confirming 
inconsistency in the rates of loss of function (and mass), due to innate biological 
variability and differing degrees of habitual physical activity, nutritional state and 
independence in activities of daily living. Indeed in some older human beings strength 
is maintained over a number of decades (Rantanen et al. 1998; Greig, Botella, & 
Young 1993). 
 
1.6.3 Changes in protein turnover with ageing 
There has been some debate whether basal rates of protein synthesis change with 
age, but it is now widely accepted that this is not the case. Opponents (Welle, 
Thornton, & Statt 1995; Hasten et al. 2000; Balagopal et al. 1997) suggest that, with 
ageing, individual muscle proteins respond in an aberrant fashion (i.e. myosin heavy 
chain or sarcoplasmic proteins demonstrate diminished synthesis rates with ageing but 
other proteins respond as per young muscle), but inconsistencies between reports 
places great doubt over their validity. Workers reporting no difference in basal 
synthesis rates have done so consistently for all muscle fractions (Katsanos et al. 
2006; Volpi et al. 2000; Yarasheski et al. 1999; Cuthbertson et al. 2005; Volpi et al. 
2001). Most authors agree that MPB does not differ with senescence in the PA state 
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(Hasten et al. 2000; Welle, Thornton, & Statt 1995; Volpi et al. 2000; Volpi et al. 2001; 
Yarasheski, Zachwieja, & Bier 1993).  
 
Response to amino acids 
When studied under absorptive conditions, older human beings do not demonstrate the 
same amplitude of response to protein feeding as seen in the young (Katsanos et al. 
2006; Paddon-Jones et al. 2004; Cuthbertson et al. 2005; Volpi et al. 2000). This 
“anabolic blunting” appears to be underpinned by dampened phosphorylation 
responses within the AA driven anabolic signalling pathways, specifically involving 
mTOR, (Cuthbertson et al. 2005) and suggest that, in older subjects, the ability to 
acquire muscle protein is likely to be less at a given availability of amino acids than in 
the young.   
 
Nevertheless some workers report no anabolic blunting with ageing. One such report, 
where each volunteer was fed an identical minced-beef patty, demonstrated no 
difference in FSR response to feeding between the groups aged 41 ± 8 y and 70 ± 5 y, 
over a 5 h period (Symons et al. 2007). However the participants in the older group 
were significantly lighter (70 kg, compared with the mean weight of young participants 
of 88 kg) and thus had a smaller volume of distribution, as demonstrated by plasma 
EAA and leucine concentrations which, at their peak, were nearly double that of the 
young. Paddon-Jones et al. also reported no difference in anabolic responses with 
ageing following a set dose of EAA (15 g), albeit their young and old volunteers were of 
similar BMI (Paddon-Jones et al. 2004). Change in plasma insulin concentration in 
response to feeding was significantly lower in the older group, whereas the intracellular 
concentrations of phenylalanine were higher (old: 150.2 ± 19.4 vs. young: 115.6 ± 5.4 
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mg Phe.leg-1). Leucine values were not published but it is fair to assume they parallel 
that of phenylalanine. Thus plausibly differences in intracellular availability of 
phenylalanine (and possibly leucine) may account for comparable rates of MPS in 
young and older participants. Indeed in a recent review, the same authors promote the 
role of anabolic blunting in the progression of sarcopenia (Paddon-Jones et al. 2008). 
 
Very high leucine concentrations may overcome anabolic blunting providing a further 
explanation of discrepant data. Two separate studies from the same research group 
confirmed no difference in anabolic responses with ageing when plasma leucine 
concentrations were raised by 3-fold (Volpi et al. 1999; Drummond et al. 2008). In the 
more recent study plasma leucine concentrations were higher in the older participants 
but intracellular concentrations did not differ; whereas in the preceding work, plasma 
concentrations did not differ between the groups suggesting that anabolic blunting may 
be overcome with a high degree of stimulation. This hypothesis is supported by data 
from old rats fed chow supplemented with leucine; anabolic responses were in keeping 
with that of adult rats, whereas data from old rats fed control chow remained blunted 
(Combaret et al. 2005). Unfortunately a 3 month period of leucine supplementation (7.5 
g.d-1) has no effect upon body composition or muscle strength in older men, although 
its effect upon protein metabolism has not been measured (Verhoeven et al. 2009). 
 
Response to exercise 
Anabolic responses to exercise also appear blunted in older human beings. Fit active 
older adults fail to elicit the doubling of FSR seen with exercise in their younger 
counterparts, although some data suggests that responses may be normalized after a 
relatively short training programme (Yarasheski, Zachwieja, & Bier 1993; Hasten et al. 
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2000) or that the latency period may differ with senescence (Drummond et al. 2008). 
Despite this, investigators have consistently reported anabolic blunting at 3, 6 and 24 h 
after exercise over a wide spectrum of exercise intensities, to the order of ~30 % 
(Kumar et al. 2009). Even data collected after participants had undergone a 3 month 
intensive resistance exercise programme confirmed anabolic blunting. Here myofibrillar 
FSR measurements taken 24 h post exercise bout were markedly diminished in older 
volunteers (0.062 ± 0.005 vs. 0.045 ± 0.005 %.h-1) (Welle, Thornton, & Statt 1995). 
These findings are supported by signalling data in rats: GSK 3α and 4E-BP1 
phosphorylation measured 6 h after high frequency electrical stimulation (a surrogate 
for exercise) were markedly diminished with older rats (Funai et al. 2006).  
 
The two groups which oppose the concept of senescent anabolic blunting following 
exercise took measurements following a 2 w exercise programme. Hasten et al. report 
a greater anabolic response in older participants than the young, (measured 3 h after 
exercise at the end of a 2 w exercise programme) with changes in FSR of 166 % and 
102 % increase over basal values respectively (Hasten et al. 2000). Whereas 
Yarasheski et al. report no difference in anabolic responses to exercise, with both 
young and older participants exhibiting a rise of ~50 % over basal values (Yarasheski, 
Zachwieja, & Bier 1993). Nevertheless data from both groups requires careful 
interpretation as exercise performed in the previous few days (which is not clearly 
stated) will have influenced the rate of anabolism. If time course changes are ignored, 
these data may also be explained by acceleration of anabolic responses in muscle 
which was untrained just 2 w earlier, particularly so in the older volunteers. The issue of 
anabolic blunting in response to either AA or exercise in trained older healthy 
volunteers is currently being addressed in an RCT.  
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Response to insulin 
Suppression of whole-body protein breakdown by insulin also appears blunted with 
senescence. At equivalent insulin and amino acid concentrations, rates of whole body 
protein breakdown are increased when compared with the young, although less so at 
higher insulin concentrations (Guillet et al. 2004b; Boirie et al. 2001). Measurements of 
leg balance and leg protein breakdown (LPB), assumed to be due mainly to muscle, 
are not different in the basal state in young and older subjects (Volpi et al. 2001). 
However it is plausible that during the fed state, when insulin secretion is stimulated, 
normal inhibition of proteolysis by insulin may occur to a lesser degree with ageing. 
This hypothesis has not been tested, but will be addressed in Chapter 5 of this thesis. 
  
1.7 Cachexia 
Cachexia presents with the same spectrum of symptoms (mostly attributed to disease 
driven cytokine production) in a wide variety of different diseases, which may be as 
diverse as cancer and renal failure. Nevertheless, cachexia carries a poorer prognosis 
than the stage of disease alone would confer, regardless of the aetiology. 
 
1.7.1 Defining Cachexia 
The spectrum of symptoms collectively termed cachexia, or the cachexia-anorexia 
syndrome by some authors, underpin the problems in accurately defining the condition. 
Rather than change in one easily measurable variable such as LBM, as occurs in 
sarcopenia, other features must also be taken into account. These may include 
anorexia, nausea, early satiety, fatigue, excessive sweating, asthenia and dyspnoea in 
addition to muscle wasting; although distinguishing between symptoms due to cachexia 
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and that of the underlying pathology, can be difficult. Indeed the lack of diagnostic 
criteria is in part due to the fact prognostic implications of each component of cachexia 
are unknown. Is the outcome worse if more symptoms are present, or if the degree of 
weight loss is greater?  
 
Weight loss is often chosen as a marker of cachexia as it is readily quantified and, in 
health, remains static for many years providing a bench mark for the pre-morbid 
condition. Some investigators have defined cachexia as unintentional weight loss of 7.5 
% healthy body weight over a 6 month period (Anker et al. 1997) while others have 
used 5 % (Kondrup et al. 2002) or 10 % (Fearon, Voss, & Hustead 2006) change over 
the same duration. These values are in essence arbitrary as the cachectic process 
begins before loss of total body weight (TBW) is evident, as demonstrated by metabolic 
changes (Pisters & Pearlstone 1993). In addition changes in total body water may 
disguise weight loss: fluid retention alone may account for 10 – 20 % of body weight 
(Hall I, Pollard BJ, & Campbell IT 1992).  A further definition based upon weight uses a 
BMI threshold of <18.5 kg.m-2 associated with unintentional weight loss, in keeping with 
the World Health Organisation definition of undernutrition (Shetty & James 1994). This 
definition selects out those individuals with severe cachexia or whose pre-morbid 
weight was at the lower end of the normal spectrum, but excludes the cachectic obese 
and those with early cachexia.  
 
Fearon et al. confirmed the short-comings of using TBW in isolation (Fearon, Voss, & 
Hustead 2006). Investigators assessed the prognostic and functional impact of three 
separate variables, weight loss, food intake and C-reactive protein (CRP), in patients 
with pancreatic cancer cachexia. No difference was demonstrated in terms of LBM, 
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quality of life (QOL) or inflammatory status when individuals were assigned to groups 
based upon the degree of weight loss alone. However, abnormal values for all three 
variables were associated with a significant decrease in QOL, LBM and health status. 
In terms of prognosis, Karnofsky performance scores (KPS; see Appendix 2), LBM, 
health status, food intake and CRP were all indicative of a worse outcome whereas 
degree of weight loss alone was not; thus supporting the hypothesis that weight loss 
alone is not sufficient to diagnose cachexia.  
 
Experts within the field of cachexia research agree that a definition is required and 
work is underway (Springer, von Haehling, & Anker 2006). For the purposes of work 
described in this thesis, “cachectic” participants have been selected providing there is 
evidence of body composition changes, although an arbitrary threshold has not been 
used for the reasons given above.  
 
1.7.2 Prevalence and rates of muscle loss in cachexia 
Conservative estimates of cachexia prevalence, using reported unintentional weight 
loss to identify cases, lie between 10 and 40 % for patients with renal, respiratory, 
cardiac, rheumatological and malignant diseases (Table 1.2) (Morley, Thomas, & 
Wilson 2006). The prevalence of cachexia in patients with critical illnesses, such as 
sepsis, burns, multi-organ failure and trauma, is more difficult to ascertain as rapid 
muscle loss occurs over a shorter duration in these patients, usually from a healthy 
baseline weight.  
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 In a critical care environment, ultrasound measurements taken from 50 patients at 
mid-arm, fore-arm and thigh revealed the median rate of muscle loss was 1.6 %.d-1 
(range 0.2 - 5.8 %.d-1) with more muscular patients losing muscle at a greater rate than 
their less muscular counterparts (Reid, Campbell, & Little 2004). This rate of wasting is 
in keeping with earlier reports of 1 - 9 %.d-1 in critically ill patients (Campbell et al. 
1995; Newsome, Mason, & Pruitt 1973; Streat, Beddoe, & Hill 1987). Compare this with 
the rate of 0.5 - 2 % per annum seen in ageing. 
 
Table 1.2 Prevalence rates of cachexia 
 
Disease process Patients affected by 
cachexia 
Chronic renal failure 40 % 
Malignancy 30 % 
Chronic respiratory disease 20 % 
Cardiac disease 20 % 
Rheumatoid disease 10 % 
 
(Morley, Thomas, & Wilson 2006) 
Chronic inflammatory disorders including inflammatory bowel disease, rheumatoid 
arthritis, fibrosing and obstructive lung diseases, cirrhotic liver disease and congestive 
heart failure are associated with a more insidious loss of lean tissue. In many cases the 
rate of muscle wasting follows the relapsing-remitting course of the underlying 
inflammatory process, with periods of relative recovery during times of disease 
quiescence. Thus there is a paucity of longitudinal data and cross-sectional studies are 
flawed by very small sample sizes.  
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A good quality cross-sectional study was conducted in children and young adults with 
Crohn’s disease (Burnham et al. 2005); body composition data from 104 patients was 
compared with that from 233 healthy age-matched controls. Fat mass did not differ 
between the groups whereas the lean mass of Crohn’s patients was 6 % less than 
healthy controls, regardless of height, age, race and gender. Furthermore an inverse 
correlation existed between activity of disease and lean mass.  
 
1.7.3 Effects of cachexia upon protein turnover 
Only a small amount of muscle metabolism work has been carried out in patients with 
wasting due to disease, rather than ageing. The existent data are predominantly drawn 
from patients with cancer and involve small numbers of subjects, a lack of homogeneity 
in those studied, and techniques that have largely been superseded. Nevertheless, 
whole-body protein turnover (WBPT) in patients with wasting due to cancer 
demonstrates, for the most part, no difference when compared with healthy controls in 
both fasted (Dworzak et al. 1998; Richards et al. 1993; Heslin et al. 1992) and fed 
(Emery et al. 1984; Heslin et al. 1992) states, although data suggesting that turnover is 
increased is also reported (Shaw et al. 1991; Melville et al. 1990; Jeevanandam et al. 
1984; O'Keefe et al. 1990; McMillan et al. 1994). Studies of patients with congestive 
cardiac failure (Toth & Matthews 2006; Norrelund et al. 2006), cirrhotic liver disease 
(O'Keefe et al. 1990) and Crohn’s disease (Motil et al. 1982) also show no difference, 
in terms of WBPT data, from healthy controls. However, whole body synthesis and 
breakdown data, in patients with inflammatory bowel disease, is increased in proportion 
to the degree of inflammation (Powell-Tuck et al. 1984).  
 
Chapter 1 
 68 
Muscle specific protein turnover is even less well studied, but observations are 
consistent. Measured under PA conditions in malignant disease, Dworzak et al. 
(Dworzak et al. 1998) reported a 60 % reduction in MPS in four patients with advanced 
gastric cancer compared with control data. These findings are supported by work in 
cachectic MAC 16 (Smith & Tisdale 1993) and XK1 (Emery, Lovell, & Rennie 1984) 
tumour-bearing mice models, in which PA MPS is suppressed by ~60 %.  Recent data 
from eleven weight stable human beings with colon cancer concur with these findings 
in that there is ~40 % reduction in MPS in the PA state (Rennie et al. 2007). The 
anabolic response to feeding is completely suppressed in these cancer patients, in 
keeping with older data (Emery et al. 1984), but is restored to normal values upon 
resection of the tumour. MPB in cancer patients does not appear to differ from normal 
values whether measured by D5 phenylalanine kinetics (Rennie et al. 2007) or 3-
methyl-histidine flux (Lundholm et al. 1982). This pattern of depressed MPS with 
preservation of MPB extends to non-malignant disease. Three-methylhistidine efflux (a 
marker of MPB) across the leg in patients with emphysema does not differ to that of 
healthy control subjects, although PA MPS is depressed (Morrison et al. 1990).  
 
1.8 Pathophysiology of sarcopenia and cachexia 
Loss of muscle tissue, whether due to ageing or disease, results from changes in 
muscle protein turnover as already described; the influences which manipulate the 
rates of protein synthesis and breakdown are more complex and less well understood. 
The degree of inflammation, provision of nutrients, habitual level of physical activity 
performed, prescribed medications and hormonal disturbances are key factors in the 
maintenance of muscle tissue. However, insulin resistance, whether a direct result of 
the underlying disease or its consequences (e.g. the result of inflammation or 
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glucocorticoid administration), appears pivotal in the control of muscle protein turnover 
(Figure 1.4). 
 
 
Figure 1.4  Factors involved in ageing and disease related loss of muscle tissue. (MPS 
muscle protein synthesis; MPB muscle protein breakdown; BMR Basal metabolic rate) 
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1.8.1 Insulin resistance 
Insulin sensitivity decreases with ageing (Boirie et al. 2001; Pagano et al. 1996; 
Dardevet et al. 1994; Elahi et al. 1993; Broughton et al. 1991; Jackson et al. 1988; 
Rowe et al. 1983; DeFronzo 1979), albeit in many cases with few objective signs of 
glucose intolerance (i.e. fasting hyperglycaemia and elevated insulin:glucose ratios). 
Reduced muscle mass, increased adiposity, inactivity and intercurrent illnesses are 
partly responsible by enhancing chronic low-grade inflammation in healthy older 
populations (Grimble 2002; Bruunsgaard & Pedersen 2003). This inflammation is 
believed to underpin insulin resistance (Yudkin et al. 1999; Festa et al. 2000).  
 
To varying degrees, insulin resistance is also universally recognized in acute and 
chronic disease (Kahn 1978). Nearly all patients with established cirrhotic liver disease 
have evidence of insulin resistance (Petrides et al. 1998) as do approximately 50 % of 
non-diabetic patients with hypertension (Ginsberg 2000). To an extent disease activity 
correlates with inflammation and consequent propensity towards insulin resistance; 
although in some diseases inflammation may be the underlying cause rather than 
effect, such as chronic kidney disease or arthrosclerosis (Howard et al. 1996; Ritz 
2008). Nevertheless, the presence of inflammatory mediators, including TNFa, IL-6 and 
CRP, appear to underpin an insulin resistant state. 
 
To date investigators have been unable to clearly localise the site of insulin resistance 
within cellular signalling pathways; although it is believed to be contained within the 
PI3K pathway, rather than Grb2-Sos-Ras. Insulin resistance of protein metabolism 
differs from that of carbohydrate metabolism and it is plausible that different defects 
maybe responsible. Lack of a clear signalling defect in carbohydrate metabolism has 
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led to suggestions that a global reduction in kinase activities (perhaps at the lower end 
of the normal spectrum) accompanied by environmental triggers, such as ill-health or 
high insulin concentrations, explain poor signal transduction without evidence of 
specific defects (Pessin & Saltiel 2000). Other proposals include a reduction in the 
number of insulin receptors (IR), down-regulation of IR kinase activity through 
serine/threonine phosphorylation, diminished IRS tyrosine phosphorylation or defects in 
the association of IRS-1 with PI3K (Cusi et al. 2000). Nevertheless, TNFα has been 
shown to inhibit insulin signalling by enhanced serine phosphorylation of IRS-1 (thus 
reducing its kinase activity) (Hotamisligil et al. 1996); thus providing one mechanism by 
which inflammation impairs insulin sensitivity.   Much less is known about insulin 
resistance of protein metabolism. 
 
Researchers have clearly demonstrated that insulin availability has no additional effect 
upon MPS in healthy young volunteers (Greenhaff et al. 2008); however the effects of 
insulin upon anabolic blunting have not been properly examined. Volpi et al. used a 
50:50 oral preparation of glucose and amino acids in order to produce an endogenous 
hyperinsulinaemic state in young and elderly individuals (Volpi et al. 2000). Under 
these conditions endogenous hyperinsulinaemia failed to elicit comparable rates of 
synthesis in young and older adults, indeed FSR did not exceed basal values in the 
older group. This is at odds with data from other groups, where a blunted, rather than 
absent, synthetic response to AA feeding has been reported (Cuthbertson et al. 2005; 
Welle et al. 1993; Balagopal et al. 1997). Further experiments are required to elucidate 
whether anabolic blunting may be overcome by the administration of high dose insulin 
and will be addressed in Chapter 4 of this thesis.  
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1.8.2 Nutrient provision 
Muscle wasting, regardless of other aetiological factors, is accelerated by inadequate 
provision of nutrients. However, excessive provision of AA results in energy surplus 
and subsequent increases fat mass rather than lean tissue, as demonstrated by 
aggressive parenteral nutritional support (Streat, Beddoe, & Hill 1987).  To identify 
patients at risk of inadequate nutrition, two screening tools are recommended for 
hospitalized patients – Malnutrition Universal Screening Tool 
(www.bapen.org.uk/pdfs/must/must_full.pdf) and Nutrition Risk Screening 2002 
(Kondrup et al. 2003) - and a third is appropriate for screening older people in the 
community – Mini Nutritional Assessment (Guigoz, Vellas, & Garry 1996). These tools 
provide a simple means for nursing staff to assess nutritional risk and identify patients 
who require referral to dietetic services for a comprehensive nutritional assessment. 
Nevertheless, individuals with isolated deficiencies in vitamins and minerals, which 
include up to a third of over 65 y olds living independently (Stroud, Duncan, & 
Nightingale 2003), are not identified using these tools.  
 
1.8.3 Exercise 
Inadequate physical activity exacerbates muscle loss regardless of the underlying 
cause. However, even individuals who continue to be physically active throughout life 
demonstrate decreases in functional ability and muscle mass (Roth, Ferrell, & Hurley 
2000), which emphasizes the importance of maintaining, or even increasing, activity 
levels with senescence. Unfortunately social isolation, lack of confidence and 
intercurrent illnesses often reduce physical activity in high risk individuals.  
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Many patients with chronic diseases are reluctant to participate in exercise programs 
although the potential benefit is greatest in these individuals. For example, patients 
with chronic renal insufficiency and low protein dietary restrictions not only benefit from 
muscle mass accretion from resistance exercise training, but also improved metabolic 
function. These patients were capable of achieving a work rate of up to 80 % 1RM 
during a 12 w supervised exercise programme, which improved protein utilization and 
enabled maintenance of baseline weight (not seen in the sham group) and resulted in 
hypertrophy of muscle fibre cross sectional area (Castaneda et al. 2001).  
 
Exercise may also modify the underlying disease process. Insulin resistance, 
atheromatous disease and inflammation are reduced directly by exercise. A single bout 
of resistance exercise improves insulin sensitivity by 13 ± 5 % (Koopman et al. 2005). 
Risk and risk of recurrence of malignancy is also reduced. Colon cancer risk falls by 
more than 20 % in both men and women that are physically active (Samad et al. 2005) 
and the reduction in mortality and disease recurrence following the diagnosis of 
malignancy approaches 50 %, regardless pre-morbid activity levels (Meyerhardt et al. 
2006a; Meyerhardt et al. 2006b). Furthermore, intensive exercise programmes improve 
self-esteem, muscle strength and tolerance of chemotherapy regimes in patients with 
malignancy (Courneya et al. 2007). 
 
1.8.4 Anabolic hormones 
Changes to circulating hormone concentrations with ageing and disease influence 
muscle maintenance. In critical illness the anabolic hormones testosterone and growth 
hormone are suppressed whilst the catabolic hormone cortisol is markedly increased 
(Vanhorebeek & Van den 2004). With healthy ageing, the production of testosterone 
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diminishes in men (Harman et al. 2001) and hypogonadism and low testosterone 
production are associated with a greater risk of sarcopenia (Szulc et al. 2004). In 
women, the decline of muscle mass is greatest after the menopause possibly because 
oestradiol conversion to testosterone is diminished, accounting for the relative 
preservation of muscle mass with the use of hormone replacement therapy (Cauley et 
al. 1987; Greeves et al. 1997). Although, older men loose appendicular (i.e. limb) 
muscle mass more rapidly than women (Zamboni et al. 2003; Gallagher et al. 1997; 
Hughes et al. 2002), despite 10-fold greater concentrations of free testosterone.  A 
difference in the basal rates of MPS (~30 % higher in women than men), may account 
for this sexual dimorphism (Smith et al. 2008). 
 
1.8.5 Pre-morbid body composition 
Those at greatest risk of morbidity due to muscle loss are those with the lowest pre-
morbid muscle mass. The prevalence of sarcopenia is two-fold greater in women than 
men (Janssen et al. 2004a) yet loss of appendicular muscle mass with ageing is 
greater in men, reflecting the smaller peak life-time muscle mass in women. This 
principle extends to veteran weightlifters who lose muscle protein mass at about the 
same rate as sedentary individuals, but retain muscle strength for longer and suffer 
less disability (Pearson et al. 2002). 
 
Obesity is also protective against sarcopenia, both in terms of age and disease related 
muscle loss, perhaps reflecting the effect of excessive nutrient provision over many 
years, although data does not tease out the effect of peak muscle mass rather than 
obesity per se. Nevertheless mortality from congestive cardiac failure following 
hospitalization is profoundly reduced with increasing BMI – including in individuals who 
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are morbidly obese - such that, in a study of over 100,000 patients, mortality was 
reduced by 10 % with every 5 kg.m-2 rise in BMI (Fonarow et al. 2007). Fewer patients 
with chronic obstructive pulmonary disease (COPD) have been studied but again lower 
mortality is seen with greater BMI (Hallin et al. 2007). 
 
There is emerging evidence that intrauterine influences affect muscle mass in later life. 
A positive correlation between birth weight and LBM has been found in men and 
women living in geographically distinct areas within the UK (Gale et al. 2001; Sayer et 
al. 2004). Adult grip strength also shows a strong positive correlation with birth weight 
(Sayer et al. 2004; Kuh et al. 2002). Aside from genetic constraints, maternal age (less 
than 17 and above 35 years), poor nutrition (especially a low protein diet), smoking, 
alcohol consumption and parity all reduce birth weight in otherwise healthy 
pregnancies, and hence may play a role in modelling gestational muscle development, 
and thus setting future risk of sarcopenia.  
 
1.8.6 Medications and other toxins 
Alcohol consumption, cigarette smoking and administration of some prescribed 
medications appear to increase sarcopenia risk, either through direct myocyte toxicity 
or through influences upon muscle protein turnover.  
 
A positive association has been described between smoking and low muscle mass 
(Szulc et al. 2004), in part due to the effects of smoking upon TBW. On a cellular level, 
smoking decreases oxidative capacity and increases type IIx fibre proportion in muscle 
(Orlander, Kiessling, & Larsson 1979). Protein turnover data from apparently healthy 
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volunteers who smoked heavily (more than 20 pack years) demonstrate a reduced rate 
of MPS in the PA state (Petersen et al. 2007); however when compared to control data, 
the smokers had significantly lower forced expiratory volumes and greater residual 
volumes, suggesting that they were developing pulmonary changes consistent with 
early COPD. Thus it is unclear whether smoking increases the risk of sarcopenia 
through low grade inflammatory changes related to the onset of COPD or due to direct 
myocyte toxicity. 
 
In contrast, alcohol appears directly toxic to skeletal muscle. Prolonged alcohol 
exposure leads to catabolism of muscle, through both enhanced MPB (Martin et al. 
1985; Preedy et al. 1989) and a reduction of MPS responses to AA feeding (Lang et al. 
2003; Lang et al. 1999). Acute alcohol exposure increases the expression of E3 ligases 
but does not appear to induce proteolysis (Vary, Frost, & Lang 2008); thus moderate 
alcohol intake is unlikely to have a significant impact on the rate of muscle decline, 
although there is no data to confirm this suggestion. 
 
Endogenous steroid hormones are, for the most part, anabolic; however 
corticosteroids, specifically glucocorticoids, when present in excessive concentrations 
are profoundly catabolic. This is well demonstrated in patients who demonstrate 
proximal limb weakness and muscle wasting with Cushing’s syndrome, or with chronic 
exogenous glucocorticoid use. Enhanced MPB (Lofberg et al. 2002) appears primarily 
responsible although inhibition of MPS is also thought to occur (Odedra & Millward 
1982). This inhibition of MPS may reflect increased insulin resistance as a secondary 
complication of glucocorticoids rather than a primary defect. Glucocorticoid 
administration also expedites muscle loss and weakness due to immobility alone by as 
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much as 3-fold. This is predominantly due to changes in MPB rather than synthesis 
(Ferrando et al. 1999).  
 
Glucocorticoids modulate cell physiology by interacting with transcription factor control 
of gene expression. In skeletal muscle, glucocorticoids are known to interfere with the 
transcription factors Myogenin, ATF4, FOXO and REDD1. Myogenin, which is involved 
in the differentiation of satellite cells, and ATF4, which facilitates AA transport into the 
cell and synthesis of non-essential AA and aminoacetyl tRNA, are both suppressed by 
glucocorticoids, whereas  REDD1, a repressor of mTOR, and FOXO are activated 
(Schakman, Gilson, & Thissen 2008). As only FOXO is involved in MPB, this data 
supports suggestions by Odedra et al. that diminished MPS also plays a role in 
glucocorticoid associated muscle loss. 
Other drugs used in immunosuppressant therapy may also impede anabolism. 
Theoretically rapamycin (also termed sirolimus) should impair muscle anabolism 
through the mTOR pathway. Current data supports this notion, but is limited to 
signalling work in rats: pre-treatment with rapamycin reduces nutrient stimulated 
phosphorylation of mTOR, eIF4G and P70S6K (Vary et al. 2007). Nevertheless, 
rapamycin is not used routinely in transplant patients due to poor tolerability: ~30 % of 
liver transplant recipients discontinue therapy due to side-effects (Rowe, Gunson, & 
Thorburn 2009).  The more commonly used calcineurin inhibitors, ciclosporin and 
tacrolimus, also appear detrimental to muscle preservation as they inhibit the NF-AT 
(nuclear factor of activated T cells) pathway which controls the differentiation of slow-
twitch muscle fibres (Naya et al. 2000). This has been shown in transplant patients 
immunosuppressed with ciclosporin, in the form of skeletal myopathy (Goy et al. 1989). 
Furthermore, mice administered ciclosporin prior to hind limb loading experiments fail 
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to demonstrate muscle hypertrophy as seen in controls (Rumpf & Henning 1990). 
Nevertheless, no protein balance data is available for these or other 
immunosuppressant agents.  
 
Beta (β) adrenoreceptor antagoinists, also known as β blockers, may also be catabolic 
and are far more commonly used than immunosuppresants, particularly in patients with 
multiple co-morbidities. Animal studies suggest β2 agonists enhance LBM by 
suppression of MPB (Costelli et al. 1995); thus β antagonism may be detrimental to the 
preservation of muscle tissue. This possibility has not been tested in human beings. 
 
1.9 Interventions to preserve muscle mass 
Avoidance of muscle-specific toxins, obtaining significant peak muscle bulk and 
avoidance of disease are key to the preservation of muscle mass. However, 
approximately a quarter of the UK population smoke (http://www.statistics.gov.uk/) and 
nearly 50 % of over 65 y olds have three or more chronic medical conditions (20 % 
have five or more) (Boyd et al. 2005). Therefore, interventions will be required for high 
risk individuals.  
 
At present the only proven, safe interventions to ameliorate loss of muscle tissue with 
ageing and disease are adequate protein intake and regular exercise (preferable 
resistance exercise). Much of the at-risk population will have been given this advice as 
part of cardiovascular disease and diabetes management, yet uptake remains poor. 
Pharmaceutical options, as described in the remainder of this section, are mostly 
experimental and not advocated for use outside of clinical trials.  
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1.9.1 Hormonal therapies 
Androgen replacement therapy has been explored using testosterone and synthetic 
analogues such as oxandrolone. In sarcopenia, testosterone replacement therapy 
appears to have only a small effect in significantly hypogonadal men (Wittert et al. 
2003). However, when used in patients with 50 – 90 % body surface area (BSA) burns, 
studied 2 and 4 w post injury, testosterone significantly reduced MPB and had no effect 
upon MPS, returning net balance to zero. There were no control data for this study but 
weight loss continues in patients with burns of this size for approximately 8 w 
(Newsome, Mason, & Pruitt 1973), implying that testosterone is markedly anabolic 
under these conditions. In health, testosterone administration appears to increase 
muscle mass through enhancing the rate of PA MPS, although feeding responses and 
breakdown data have not been collected (Griggs et al. 1989).  
 
Oxandrolone also increases PA rates of MPS in healthy volunteers, with no change in 
MPB (Sheffield-Moore et al. 1999). In both adults and children recovering from burn 
injuries, lean weight gain and muscle strength on oxandrolone is approximately double 
that of controls, resulting in reduced hospitalization (Jeschke et al. 2007; Demling & 
DeSanti 1997). However, a Cochrane review of anabolic steroid use in patients with 
HIV-associated wasting was less impressive (Johns, Beddall, & Corrin 2005). This 
meta-analysis of 13 randomized placebo controlled trials, involving over 1000 patients, 
reported inconsistent results across the studies and a mean increase of just 1.1 kg 
TBW, (1.3 kg LBM) on active treatment. Taking into account the potential side-effects 
of androgen use, which include virilization (i.e. deepening of the voice, hirsutism, acne 
and clitoromegaly), hepatotoxicity (including peliosis hepatitis, cholestatic hepatitis and 
tumours), fluid retention, prostatic hypertrophy and carcinoma, hypercalcaemia and 
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bleeding diatheses (due to suppression of clotting factors II, V, VII, and X) wide-spread 
use is not advocated. Hepatotoxicity and virilization are said to be less prevalent with 
oxandrolone yet risks still out-weigh benefits for use in sarcopenia (Orr & Fiatarone 
2004). 
 
The progesterones, medroxyprogesterone and megestrol acetate, have been used for 
their appetite stimulating properties which are thought to be the result of cytokine 
suppression (Mantovani et al. 2001; Inui 2002). Nevertheless, benefits are limited to 
weight gain rather than restitution of LBM or strength as confirmed by placebo 
controlled trials in cachexia due to COPD (Weisberg et al. 2002), end-stage 
malignancy (Feliu et al. 1992; Bruera et al. 1990) and HIV (Oster et al. 1994; Von 
Roenn et al. 1994).  In addition, the side-effect profile (fluid retention, mood changes, 
hyperglycaemia, adrenal insufficiency and venous thrombo-embolism (VTE)) limits 
wide-spread use. 
 
Stimulation of anabolism with growth hormone (GH) has been trialled by a number of 
investigators, initially with promising results. In healthy volunteers and post-operative 
patients, GH appears to increase insulin-like growth factor 1 and nitrogen balance 
(Dahn, Lange, & Jacobs 1988; Sevette et al. 2005; Lehmann et al. 1990); however a 
large study of critically ill patients revealed that GH increased mortality (Takala et al. 
1999), possibly the result of increased insulin resistance and hyperglycaemia.  
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1.9.2 Tumour necrosis factor alpha antagonism 
Direct tumour necrosis factor alpha (TNFα) inhibition has been investigated in muscle 
wasting with pentoxyphylline, infliximab and thalidomide. Both pentoxyphylline (Biolo et 
al. 2002) and infliximab (a monoclonal antibody against TNFα) (Steiner et al. 2007) 
suppress proteolysis; however infliximab also suppressed MPS therein leaving net 
balance unchanged. Neither weight gain nor appetite improvements were seen with 
pentoxyphylline use in patients with solid tumours when compared with placebo over 
an 8 w period (Goldberg et al. 1995).  
 
More promising data exists for thalidomide use in cancer cachexia. An open-labelled 
study of 11 cachectic oesophageal cancer patients reported an increase in LBM of 1.75 
kg after 2 w of thalidomide compared with 1.11 kg lost in the preceding 2 w on normal 
diet alone (Khan et al. 2003). Further data from a randomized controlled trial involving 
50 cachectic pancreatic cancer patients, confirmed that thalidomide significantly 
attenuated loss of total and lean weight when compared with placebo over a 4 w period 
(Gordon et al. 2005). However, neither group measured circulating blood TNFα 
concentrations or changes in protein turnover.   
 
Thalidomide is known to reduce blood TNFα concentrations by accelerating the 
degradation of TNFα mRNA transcript (Moreira et al. 1993) and prevent activation of 
nuclear factor kappa B (NFκB) through phosphorylation of its inhibitory protein IκBα 
(Keifer et al. 2001). Nuclear factor kappa B is a ubiquitous transcription factor which 
has multiple genomic binding sites and is involved in the control of cell differentiation, 
proliferation, and survival in addition to immune regulation through enhanced cytokine 
generation. Thus changes in body composition resulting from thalidomide use may 
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stem from its influences upon NFκB activity, rather than TNFα per se. Nevertheless 
further work is required to confirm the efficacy of thalidomide and elucidate the 
mechanism by which anabolism occurs. 
 
1.9.3 Other agents 
Three-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors, 
otherwise known as statins, are widely advocated in primary and secondary prevention 
of heart disease and have been shown to reduce the progression to diabetes by as 
much as 30 % (Freeman et al. 2001). A possible mechanism by which insulin 
sensitivity is maintained is the reduction of IL-6 and TNFα  production (Rosenson, 
Tangney, & Casey 1999). To date there are no metabolic studies quantifying the effect 
of statins upon muscle anabolism, but a recent abstract indicates benefit in terms of 
acquisition of LBM following resistance exercise (Riechman et al. 2007) and 
identification of individuals at higher risk of myopathy, a rare side-effect of statin use, is 
now possible by identifying a genetic polymorphism on Chromosome 12 (Link et al. 
2008). 
 
Further promise exists for melatonin use in maintenance of muscle mass. Melatonin, 
principally involved in the control of circadian rhythm, controls cell differentiation and 
proliferation, enhances immune function and has anti-oxidant effects (Brzezinski 1997). 
When given to patients with solid tumours, TNFα concentrations halve from baseline 
values and body weight is maintained over a 12 w period (Lissoni et al. 1996). A more 
recent study, which was flawed by very small numbers, confirmed melatonin’s potential 
for use as an anabolic agent, albeit with less impressive effects upon cytokine 
suppression (Persson et al. 2005). Melatonin may be of use in the management of 
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sarcopenia and cachexia as it is very well tolerated and side-effects are limited to 
hypersomnolence and ovulatory dysregulation.   
 
1.10 Research questions and hypotheses 
Despite important functions to maintain health and physical independence, muscle 
tissue is depleted during healthy ageing and many diseases by common mechanisms. 
Many of these pathophysiological processes are not fully understood; however 
anabolic blunting in response to AA appears to play critical role, particularly in slow 
wasting conditions. Enhanced proteolysis features more commonly in rapid wasting 
conditions, such as sepsis, burn injuries and advanced cancer, and is believed to be 
mediated through pro-inflammatory cytokines and catabolic hormones. Loss of LBM, 
whether due to blunted anabolism or proteolytic disease states, is compounded by 
inactivity and poor nutritional intake, which are common in unwell or older human 
beings.  Many unexplored avenues exist in this area of physiology, in part due to the 
difficulties conducting physiological research in human beings, particularly those with 
overt muscle wasting. Data from animal studies, particularly intracellular signalling from 
mouse and rat work, is not consistently applicable to human beings. Therefore a plan 
of studies was developed involving both patients with cachexia due to oesophageal 
cancer and healthy volunteers aged 18 to 33 y or 65 to 75 y. 
 
The first objective was to validate the use of thalidomide in the treatment of cachexia 
due to oesophageal cancer; specifically to ensure that the anabolic effect of 
thalidomide is superior to placebo, is sustained over a longer duration and is well 
tolerated by patients with end-stage disease. A randomized, parallel arm, placebo 
controlled trial (RCT) was designed to test the hypothesis that 200 mg of thalidomide 
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taken orally for 6 w would prevent loss of TBW, including lean tissue, in patients with 
weight loss due to oesophageal cancer.  
 
Subsequently, a mechanistic study was planned concerning the mechanisms by which 
thalidomide exerts its apparent anabolic effect, to address the following questions: 1) is 
there attenuation of MPS rates either in the basal state or in response to feeding, 
suppression of proteolysis or a combination of both processes? And 2) is the effect 
orchestrated through a reduction in pro-inflammatory cytokines concentrations, or a 
direct effect of NFκB antagonism? A subsequent, stable isotope study was designed, 
ethically approved and funded, to specifically address these questions. Recruitment 
was due to commence upon completion of the RCT; however negative findings 
(Chapter 3) cast doubt over the efficacy and tolerability of thalidomide and it was 
deemed unethical to proceed. 
 
A striking feature of anabolic blunting in sarcopenia is the defect in signalling 
responses to AA feeding, specifically mTOR and the upstream PI-3K pathway. As the 
PI-3K pathway is implicated in insulin resistance pathophysiology, it is plausible that 
increasing insulin availability above normal post-prandial concentrations would 
overcome anabolic blunting by restoring the activation of these signalling enzymes in 
older human beings.  Thus MPS measurements in young and older healthy volunteers 
under fasted and hyperaminoacidaemic hyperinsulinaemic conditions were conducted 
to test the following hypotheses:  First, administration of insulin at supraphysiological 
doses to older human beings in the presence of AA feeding restores the rate of MPS to 
that of their younger counterparts; and secondly, that phosphorylation of signalling 
proteins within the mTOR pathway would be restored.  
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The final objective, to investigate the effects of modest insulin concentrations upon 
MPB in young and older healthy volunteers, aimed to test the hypothesis that insulin-
dependent suppression of muscle specific proteolysis is blunted with ageing. As most 
of the effects of insulin upon skeletal muscle appear to have occurred at concentrations 
of < 30 µIU.ml-1, target insulin concentrations of 5 and 15 µIU.ml-1 were sought to 
achieve a degree of insulinemia comparable with that which follows a low glycemic 
index meal, such as a light breakfast.  A two phase metabolic study was conducted for 
this purpose.   
Chapter 2 
Methods 
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2.1 Clinical methods 
2.1.1 Ethical approval 
All protocols were prospectively approved by the appropriate research ethics 
committee and conducted in accordance with International Conference on 
Harmonisation (ICH) / World Health Organisation (WHO) Good Clinical Practice 
standards. Protocols of healthy volunteer studies were submitted to the University of 
Nottingham Medical School Research Ethics Committee for approval, whereas studies 
involving patients were sanctioned by Derbyshire Research Ethics Committee.  
 
2.1.2 Recruitment and screening  
Healthy volunteers were recruited from the local community by poster advertisements 
in libraries, shops, museums and leisure centres, and radio and newspaper coverage 
facilitated through the University of Nottingham press office. Patient recruitment is 
detailed in Section 2.1.11. Participant information sheets and a basic health 
questionnaire were sent out in response to healthy volunteer enquiries with an 
invitation to return the questionnaire if interest was retained.  
 
Volunteers were invited to attend the research facility before entry into the studies. At 
this visit a detailed discussion of the proposed study took place to ensure the 
participants were able to give full informed consent. Each participant underwent a full 
medical history and examination including blood pressure measurement and an 
electrocardiogram. Blood was drawn and analyzed by the hospital laboratory for the 
following screening tests: fasting glucose, full blood count, plasma electrolytes, liver 
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function tests, thyroid function tests and, for studies involving muscle biopsies, a 
coagulopathy screen.  
 
Study specific inclusion and exclusion criteria were checked at the primary visit and in 
the case of the patient study, also validated from hospital records. Healthy volunteers 
were excluded if they had evidence of heart disease, chronic pulmonary diseases, 
diabetes mellitus, malignancy or glucocorticosteroid use (within the preceding year). 
Women of child bearing age were specifically screened for pregnancy (Clearview HCG 
II, Inverness medical UK).  
 
2.1.3 Body composition measurements 
Anthropometric measurements 
All healthy volunteers and patients were studied in the postabsorptive state and wore a 
hospital gown and their underclothes for all body composition measurements. Height 
was recorded in meters using the Bedford rule; a single set of electronic scales were 
used for weight measurements. 
 
Mid-arm muscle circumference (MAMC) was calculated from triceps skin fold thickness 
(TSF) and mid-arm circumference (MAC) using the following equation: 
MAMC = MAC – π (TSF) 
(Bishop, Bowen, & Ritchey 1981) 
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MAC and TSF measurements were taken at a point equidistant from the acromion 
process and olecranon. TSF measurements were made vertically along the posterior 
midline using skin fold callipers (Holtain, Pembrokeshire, UK). The technique for these 
measurements was practiced over 50 times before the study to optimize reproducibility. 
All measurements were taken by the author to avoid inter-operator error.   
 
Dual energy X-ray absorptiometry (DEXA) 
Fan beam DEXA equipment, Lunar Prodigy II (GE Medical Systems, Buckinghamshire, 
UK), was used for all healthy volunteer studies. Subjects were positioned to ensure 
separate body compartments could be analyzed i.e. where possible a space was left 
between the legs and between arms and torso.  
 
The delineation between leg and torso, for the purpose of determining the individual leg 
volumes or appendicular lean body mass (ALBM), was defined as tissue distal to a 
horizontal line passing through the symphysis pubis (Figure 2.1). Arms were classified 
as all tissue lateral to a vertical line passing through the glenohumeral joint, where 
possible excluding breast tissue.  Leg volumes included all tissue types whereas 
appendicular lean body mass (ALBM) values were calculated from the sum of lean 
tissue within all leg and arm compartments.  
 
A pencil-beam DEXA, Lunar DPX IQ™ (GE Medical Systems, Buckinghamshire, UK) 
was used for the first 30 patient studies. This model was up-graded before completion 
of the trial hence the Lunar Prodigy II was used for the last 4 participants. All patients 
who underwent repeat studies were scanned on the same equipment. 
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Figure 2.1  DEXA images of bone (left) and soft tissue (right) with unilateral arm and 
leg regions of interest marked (rectangles).   Image taken from Lunar Prodigy II (GE 
Medical Systems, Buckinghamshire, UK). 
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2.1.4 Measurement of insulin resistance 
Fasting whole blood glucose and plasma insulin concentrations were quantified 
(Section 2.2) for all healthy volunteer studies. Insulin resistance was calculated using 
both the homeostatic model assessment for assessment of insulin resistance (HOMA-
IR) and the quantitative insulin sensitivity check index (QUICKI). 
  
HOMA-IR = [fasting insulin (µU.ml-1) x fasting glucose (mmol.l-1)] / 22.5 
(Matthews et al. 1985) 
QUICKI = 1 / [log fasting insulin (µU.ml-1) + log fasting glucose (mg.dl-1)] 
(Katz et al. 2000) 
Using the following conversion for glucose:  
X mg.dl-1 x 0.055 = Y mmol.l-1 
 
2.1.5 Stable isotope tracers 
In order to determine AA kinetics, trace quantities of stable (non-radioactive) isotope 
labelled AA (the “tracer”; Figure 2.2) were administered intravenously. [1,2 13C2]leucine 
(99% 13C) and D5 phenylalanine (98% 2H) were both manufactured by three different 
companies, dependent upon cost and lead time (Isotec, Sigma-aldrich, UK; CK Gas 
Products Ltd, Hampshire UK; Cambridge Isotopes Limited, Massachusetts, USA). 
Enriched leucine and phenylalanine were assessed to purity and sterility quality 
standards, prior to the manufacture of infusions. The required dose of each tracer was 
aseptically dissolved in 250 ml of 0.9 % saline, either individually or in combination 
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according to the specific protocol. The desired infusion rate for each tracer (Table 2.1) 
was determined by subject weight in order to obtain a constant level of pre-cursor 
labelling at ~6 %; during AA feeding the tracer infusion rate increased pro rata to 
ensure a constant level of labelling. Appropriately certified hospital pharmacy 
departments carried out quality control and tracer manufacture.  
 
 
 
Figure 2.2  Molecular structure of [D5] Phenylalaine (left) and [1,2 13C2] Leucine (right) 
 
Table 2.1 Tracer infusion rates 
Tracer Prime Continuous infusion 
[1,2 13C2]leucine 0.75 mg.kg-1 1 mg.kg-1.h-1 
D5 phenylalanine 0.3 mg.kg-1 0.6 mg.kg-1.h-1 
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2.1.6 Sample collection  
Blood sampling  
The heated hand technique was used to obtain arterialized-venous blood samples as a 
safer alternative to direct arterial sampling. This technique, from the early 80’s, involves 
placing the hand inside a heated box (~55 °C) to create an arterio-venous shunt (by 
vasodilation of veins in the fingers) enabling arterialized-venous blood sampling from a 
retrograde catheter in the dorsum of the hand (Abumrad et al. 1981). 
 
Either a peripheral or femoral vein catheter was used to collect venous blood samples. 
The femoral vein catheter was inserted by the Seldinger technique (Seldinger 1953), 
using ultrasound imaging, for direct sampling of blood draining the leg. All venous and 
arterialized-venous blood samples were collected into pre-filled vacutainer tubes 
containing either ethylenediaminetetraacetic acid (EDTA), lithium heparin or clot 
activator. Samples were immediately stored on ice until centrifuged at 2000 x g for 20 
min; plasma was stored in aliquots at -80°C for later analysis.  
Muscle sampling  
All 3 techniques for percutaneous muscle biopsy (needle (Bergström 1975), 
conchotome (Dietrichson et al. 1987) and Bard gun (Cote et al. 1992)) were observed 
by the author. Tissue samples obtained from the conchotome technique remained 
intact and were larger (~50 mg per sample) than those obtained by the other methods 
and volunteers appeared to tolerate the procedure better. Thus all biopsies were taken 
by the author using the Conchotome technique, following hands-on training (Figures 
2.3 and 2.4).  
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Muscle biopsies were all taken from vastus lateralis, ~15 cm above the distal insertion, 
under local anaesthetic (0.5 – 1 % lignocaine), with subsequent biopsies taken at least 
2 cm proximal to the last. At each time point three ~50 mg tissue samples were 
collected from the same biopsy site, at 120° from each other; samples collected for 
tracer and protein extraction were washed in ice-cold phosphate buffered saline (PBS) 
before snap frozen in liquid nitrogen. The sample collected for RNA extraction was 
immediately snap frozen, without washing. The biopsy sites were closed with 3.0 
synthetic monofilament sutures (Ethilon, Johnson & Johnson) and covered with 
shower-proof dressing for at least 72 h. For the first 24 h, wounds were also dressed 
with a compression bandage (Coban, 3M, Berkshire, UK) to minimize bruising. Sutures 
were removed at 7 d. 
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Figure 2.3  Muscle sampling from quadriceps muscle taken using the Conchotome 
technique.  
Figure 2.4  Removal of biopsy tissue from forceps by an assistant. 
2.1.7 Blood flow measurements  
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Pulsed wave doppler ultrasound (Nemio 17, Toshiba, Crawley, UK) was used to 
quantify blood flow through the common femoral artery. The angle of insonation was 
maintained at 60° or less and gate adjusted to ensure optimal sampling. Training for 
blood flow measurements was obtained from ultrasonographers within the clinical 
environment and adapted to maximize accuracy and reproducibility for the purposes of 
flow measurements. 
 
2.1.8 Pancreatic clamp 
To assess the effects of supraphysiological plasma insulin concentrations upon MPS in 
young and older individuals, the hyperinsulinaemic euglycaemic pancreatic clamp 
(DeFronzo, Tobin, & Andres 1979) was modified to achieve target insulin concentration 
of ~100 µIU.ml-1. Endogenous insulin production was suppressed by the continuous 
infusion of octretide (Sandostatin, Novartis, Camberley, UK; 30 ng.kg-1.min-1) and 
replaced with short acting insulin (Humulin S, Lilly, Basingstoke, UK; 4.3 IU.m2 BSA-1.h-
1). The pancreatic clamp technique was modified for a second time to assess the 
effects of low postprandial concentrations of insulin upon MPB. Target plasma 
concentrations for this protocol were ~5 and ~15 µIU.ml-1 and achieved by 
administering exogenous insulin at 2 and 10 µIU.m2 BSA-1.min-1 respectively.  
 
For all insulin clamps ~5 ml of the patients’ blood was added to the diluent (50 ml 0.9 % 
saline, Baxter, Thetford UK) to minimize insulin adherence to the syringe and 
administration set.  Arterialized-venous blood sampling was conducted at 5 min 
intervals to monitor blood glucose and enable titration of 20 % dextrose solution 
(Baxter, Thetford, UK) to maintain a glucose concentration of 4.5 - 5.0 mmol.l-1. After 
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the study, participants were given a high energy meal containing a mixture of simple 
and complex carbohydrates and warned of the signs and appropriate treatment of 
hypoglycaemia.  
 
2.1.9 Amino acid feeding regimes 
A mixed intravenous AA preparation (Glamin, Kabi Fresenius, Homburg, Germany) 
was used for both protocols and infused as per Table 2.2. Composition data is given in 
Appendix 3.  
Table 2.2  Glamin infusion regimes 
Protocol Prime dose Infusion rate Aim 
1 0.25 ml.kg 0.75 ml.kg-1.h-1  Double plasma [AA] 
2 none 0.19 ml.kg-1.h-1    Maintain plasma [AA] 
 
Ideally continuous AA concentration monitoring would have been carried out during 
each study, particularly where tight control of PA plasma AA concentrations were 
required. The AA analyser (Biochrom 30, Biochrom, Cambridge, UK) was not suited for 
this purpose as its run time per sample is ~20 min. Other workers have used a 
fluorometric assay to obtain results within 5 min (Chevalier et al. 2005); however, 
despite extensive experimentation, it was not possible to reproduce this technique with 
any accuracy. Therefore low dose insulin clamp studies were conducted on volunteers, 
to experiment with the timing and doses of an AA supplementation, based upon subject 
weight and glucose requirements, in order to maintain PA plasma AA concentrations.  
2.1.10 Protocols for randomized placebo controlled trial of thalidomide use in 
patients with cachexia due to oesophageal cancer  
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Study Design  
Change in TBW and LBM over a 6 w treatment period were sought as primary end-
points and assessed using a randomized parallel arm double-blind placebo control trial. 
Secondary end-points, selected to demonstrate a mechanistic explanation to underpin 
expected changes in body composition and to assess drug tolerability were resting 
energy expenditure (REE), Karnofsky Performance Scale (KPS), Piper Fatigue Score 
(PFS), routine biochemistry, blood counts and symptoms profiles. Both investigator and 
participants were blinded to the allocated treatment arm throughout the study period 
and laboratory analysis (Figure 2.5). 
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Figure 2.5  Protocol to investigate the effects of thalidomide upon body composition in 
patients with oesophageal cancer cachexia.  (NCS nerve conduction studies; KPS 
Karnofsky performance scale; TBW total body weight; REE resting energy 
expenditure). 
Screened 
NCS
Dietician 
TBW
DEXA
REE 
Anthropometry
KPS
Piper Fatigue Score
Clinical 
assessment
Clinical 
Assessment
TBW
DEXA
REE 
Anthropometry
KPS
Piper Fatigue Score
-2
0
2
4
6
Ti
m
e 
(w
ee
ks
)
Chapter 2 
 100 
Patients, inclusion and exclusion criteria 
Male and female adult patients with incurable oesophageal cancer and evidence of 
wasting were identified at a weekly multi-disciplinary meeting attended by an 
oncologist, gastroenterologist, gastrointestinal surgeon, radiologist and palliative care 
physician. Evidence of wasting was sought from weights recorded in the case notes 
and from patient recollection. All histological types were eligible, as were type 3 gastro-
oesophageal junction tumours. Suitability for study participation was considered after 
case discussion and consideration of established oncological and surgical 
interventions. It was not deemed ethical to delay potentially curative surgery for 6 w for 
the study to complete pre-operatively and therefore individuals scheduled for surgery 
where not included. Patients offered palliative endoscopic treatments for moderate to 
severe dysphagia were selected for screening.  
 
Contra-indications to thalidomide prescribing and factors preventing an adequate 
dietary intake underpinned the exclusion criteria. To eliminate the possibility of 
teratogenic sequealae pre-menopausal women were excluded and men were 
instructed to wear condoms during intercourse (thalidomide is excreted in seminal 
fluid). Thalidomide causes a progressive sensory neuropathy with prolonged use, thus 
all subjects were screened for existing peripheral nerve dysfunction. Subjects who 
demonstrated clinical evidence of neuropathy or had previous chemotherapy exposure 
underwent formal nerve conduction studies before entering the study. Sensory nerve 
action potential amplitudes of median, radial and sural nerves were recorded on two 
separate days to screen for axonal neuropathies and established a baseline for later 
comparison should patients develop neurological symptoms, as per thalidomide 
prescribing guidelines (Powell & Gardner-Medwin 1994). 
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In order to ensure participants were able to maintain adequate nutrition and complete 
the study significant untreated dysphagia (inability to swallow), on-going chemotherapy 
or radiotherapy and extreme fraility were exclusion factors. Dysphagia was assessed 
as per the Bown dysphagia score (Table 2.3) (Bown et al. 1987); patients with a score 
of 2 or less were included, as were those receiving enteral feeds (i.e. via a naso-gastric 
tube or percutaneous gastrostomy), whereas patients with grade 3 and 4 dysphagia 
attended for endoscopic thermoablative treatment or oesophageal stenting before 
randomization.  Side-effects, such as nausea and anorexia, precluded patients with on-
going chemotherapy and radiotherapy. A washout period of 4 w was required after 
oncological treatments to ensure metabolic effects, such as alterations in energy 
expenditure, had returned to baseline.  Finally patients were assessed in terms of 
mobility and estimated life-expectancy to maximise the number able to attend the 
hospital for visits at baseline and 6 w for body composition measurements. Domiciliary 
visits at 2 w intervals were offered to patients to minimise the inconvenience of 
participation.  
 
Table 2.3  Bown dysphagia score 
0 Normal swallow 
1 Difficulties with dry solids 
2 Semi-solid diet 
3  Liquid diet 
4 Complete dysphagia 
(Bown et al. 1987) 
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Study Drug  
Capsules of thalidomide and identical placebo were obtained as a gift from Pharmion 
Ltd, (Wales, UK) and stored by Derby hospitals NHS Foundation Trust Pharmacy. Male 
pharmacy staff were responsible for packaging and labelling both active drug and 
placebo and dispensed the appropriate trial medication according to the randomization 
protocol.  
 
Subjects were told they were given sufficient capsules for the study duration and asked 
to bring their trial medications to each consultation to enable assessment of 
compliance. Four capsules provided 200 mg d-1 of thalidomide or identical placebo. 
Subjects were advised to take their capsules at night to minimize the somnolence 
effects of treatment. At completion of the trial period all subjects were offered open-
labelled thalidomide which was prescribed in accordance with Pharmion’s risk 
management programme.    
 
Dietetics 
Prior to randomization, the dietary intake of each subject was reviewed by a dietician, 
after which they were established on an isocaloric diet over a 10 d run in period, based 
on an estimation of the total daily energy content using the Schofield equation for REE 
(Schofield 1985) with a standard increment above the baseline to allow for activity. 
Dietary intake was monitored using a 4 d diet diary immediately before baseline testing 
and at 4 w.   
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Resting energy expenditure  
Indirect calorimetry measured using a ventilated hood apparatus (Figure 2.6; GEM, 
NutrEN technologies Ltd, Burnley, UK) was used to determine REE in 29 patients 
(equipment was unavailable for the remaining 5 patients). Recordings of expired pO2 
and pCO2 were collected over 20 min at rest. Values for REE were extrapolated over a 
24 h period and reported per kg FFM, as determined by DEXA. 
  
 
 
 
 
Figure 2.6.  Volunteer demonstrating ventilated hood apparatus for measurement of 
resting energy expenditure and heated box for arterialized-venous blood sampling. 
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Functional measurements and symptom profiles 
At each visit patients were directly questioned about symptoms of disease progression 
and adverse events. Patients were asked about appetite, ability to swallow, nausea, 
vomiting, constipation and excessive tiredness. A full examination was conducted at 
each visit, including neurological assessment, to document disease progression, 
identify concurrent illnesses, and detect adverse effects of the trial drug. New 
symptoms were classified as disease progression or drug side-effect and dealt with 
accordingly. Where symptoms were attributed to the study drug, the dose was reduced 
in the first instance (where possible) and only discontinued if symptoms persisted.  
 
The KPS (Appendix 2) (Karnofsky 1950), a graded index of physical function ranging 
between 100 % (full health) and 0 % (death), was recorded at each visit by the author. 
Whereas the PFS questionnaire (Appendix 4) (Piper et al. 1998) validated to measure 
subjective fatigue patterns, was completed independently by the subject. This research 
instrument comprises of 22 questions each scaled from 0 to 10 which subdivide into 4 
dimensions: behaviour/severity, affective meaning, sensory and cognitive/mood. Data 
collation was conducted in a blind fashion at the end of the study. 
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2.1.11 Protocols for healthy volunteer studies 
Protocol 1 Is anabolic blunting overcome in hyperinsulinaemic states? 
This study was designed to compare the anabolic response of skeletal muscle to mixed 
AA feeding under hyperinsulinaemic conditions in young and older healthy volunteers. 
Male and female healthy volunteers aged between 20 and 30 y (young) or 60 - 75 y 
(older) were included in this study. See Figure 2.7 for sampling protocol.   
 
Protocol 2 Does age affect the degree of suppression of proteolysis by insulin? 
For this protocol, target insulin concentrations of ~5 µIU.ml-1 and ~15 µIU.ml-1 were 
sought, each for 1.5 h period, while AA were maintained at PA concentrations (Figure 
2.8). To ensure sub-clinical diabetes mellitus was not present, fasting insulin and 
glucose concentrations were measured as a screening tool. The age ranges for young 
and older healthy volunteers were 18 - 33 y and 60 - 75 y, respectively. 
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Figure 2.7  Protocol to assess the effects of high dose insulin and intravenous AA 
feeding upon muscle protein synthesis, in young and older healthy volunteers (Protocol 
1). 
 
-1         0            1              2              3              4               5
Time (h)
Muscle biopsyBlood sample
[1,213C2]leucine
↑ Insulin Clamp
i.v. AA
Chapter 2 
 107 
 
 
Figure 2.8   Protocol to assess leg proteolysis at plasma insulin concentrations of ~ 5 
and ~ 15 μIU.ml-1 in young and older healthy volunteers (Protocol 2). Arterialized-
venous blood (A) was collected at ~ 5 min intervals to monitor blood glucose 
concentrations infusions. Paired samples of arterialized-venous and femoral vein blood 
(A and V) were collected at baseline and 20 minute intervals through the last hour of 
each clamp period (small arrows), preceded by doppler blood flow measurements 
(rectangles). Muscle biopsies are indicated by large arrows. 
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2.2 Laboratory methods 
 
2.2.1 General chemicals 
All chemicals, unless otherwise specified, were sourced from Sigma-Aldrich (Poole, 
UK).  
 
2.2.2 Analytical methods for blood  
Hormone and cytokine assays 
Concentrations of plasma insulin (BioSource Europe S.A.), C-reactive protein (CRP) 
(BioSource Europe S.A), TNFα (Bender MedSystems) and IL-6 (DRG instruments 
GmbH, Germany), were determined by enzyme-linked immunosorbant assays (ELISA). 
Each assay was processed according to the manufacturers’ protocol.  
 
In brief, monoclonal (capture) antibodies, directed against distinct epitopes on the test 
hormone, were pre-bound to a 96-well plate, to which the calibrators and samples were 
added prior to a secondary antibody labelled with horseradish peroxidase (HRP). The 
TNFα ELISA required an amplification step at this stage in order to detect low serum 
levels, but otherwise all protocols were not dissimilar. Any unbound antibody was 
washed off the plate before a chromogenic solution, which reacts with HRP, was 
added. The reaction was stopped with hydrochloric acid and the optical density read at 
450 nm against a reference filter set at 650 nm (Multiskan Ascent plate reader with 
Ascent software v.2.6, Thermo Scientific, UK) to generate a 4 parameter logistic 
standard curve from which the sample values could then be read.  
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Whole blood glucose concentration 
Whole blood samples were used for real-time glucose analysis during clamp studies. 
Approximately 200 μl of blood was mixed for ~2 min with fluoride, heparin and nitrite, in 
pre-prepared tubes (GMRD-034, Analox instruments, London, UK) until oxidized as 
indicated by a chocolate-brown discolouration.  A sample of 10 μl was injected into the 
GM7 Stat Analyzer (Analox Instruments, UK) for measurement of oxygen consumption 
as per the following reaction:  
β-D-Glucose + O2  → D-Gluconic Acid + H2O2 
  GOD    
GOD = glucose oxidase 
Both 5 and 8 mM standards were used as calibrants. 
 
Free fatty acid measurement 
Plasma free fatty acids were measured using a colorimetric assay (Roche Applied 
Science, Indianapolis, USA). 
 
Plasma amino acid labelling 
To determine labelling (atoms % excess; APE) and concentration of arterialized-
venous and venous leucine, phenylalanine and α-ketoisocaproate (α-KIC), plasma was 
deproteinised with 100 % ethanol, dried and, for amino acid analysis, re-suspended in 
0.5 M HCl. Lipids were removed by ethyl acetate extraction and then converted to their 
tert-butyldimethylsilyl (t-BDMS) derivatives. α-KIC was converted to its quinoxalinol 
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derivative and separated by extraction into ethyl acetate, which was then evaporated 
and the t-BDMS derivative prepared. Concentrations and enrichments were determined 
by gas chromatography-mass spectrometry (GC-MS) using a Trace DSQ GC-MS 
(Thermo Fisher Scientific, Hemel Hempstead) using appropriate internal standards.   
 
Amino acid analysis 
Equal volumes of plasma and 10% sulphosalicyclic acid were mixed and cooled at 4°C 
for 30 min. The samples were spun to remove the precipitated protein and passed 
through a 0.22 µm filter prior to analysis on an amino acid analyser (Biochrom 30, 
Biochrom, Cambridge, UK) using a lithium buffer separation. All 20 AA concentrations 
were determined by comparison to a standardized sample, using norleucine as an 
internal standard. 
 
2.2.3 Analytical methods for muscle 
Myofibrillar protein isolation 
Approximately 30 mg of muscle was minced finely using pointed scissors in ice-cold 
extraction buffer (0.02 M Tris, 0.15 M NaCl, 0.1 M EDTA, 0.1% Triton X). The 
homogenate was centrifuged at 1,600 × g for 20 min to remove the supernatant with 
subsequent resuspension of the myofibrillar/collagen pellet in 0.3 M NaOH. The soluble 
myofibrillar protein and the insoluble collagen were separated by centrifugation. The 
myofibrillar fraction was precipitated using 1M perchloric acid and the pellet washed 
twice with 70 % ethanol. Myofibrillar protein was hydrolysed in 0.05 M HCl/Dowex 
50W-X8-200 at 110°C overnight (Balagopal, Nair, & Stirewalt 1994), and the liberated 
amino acids were purified then eluted in 2 M NH4OH. The amino acids were 
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subsequently derivatized as their N-acetyl-n-propyl (NAP) ester (Meier-Augenstein 
1999). Leucine labelling was analysed by capillary gas chromatography combustion 
isotope ratio mass spectrometry (GC-C-IRMS; Delta-plus XL, Thermo Fisher Scientific, 
Hemel Hempstead, UK); separation was achieved on a 25 m x 0.25 mm x 1.0 µ film DB 
1701 capillary column (Agilent Technologies, West Lothian, UK). 
 
Extraction of protein for Western Blotting 
For protein extraction 30 - 40 mg of each muscle sample were minced then 
homogenized for 30 sec in ice cold buffer (10 μl.mg-1 muscle) containing 50 mM Tris 
HCl, 0.1 % Triton X-100, 1 mM EDTA, 1 mM EGTA, 0.1 % 2-mercaptoethanol, 10 mM 
ß-glycerophosphate, 0.5 mM sodium orthovanadate and complete protease inhibitor 
cocktail (Roche). A Bradford assay was used to quantify the protein concentration of 
the supernatant prior to denaturing with Laemmli buffer at 95°C for 5 min. 
 
For PKB kinase activity, PKB was immunoprecipitated from 300 µg protein before 
incubation with 1 mM ATP and GSK3β fusion protein substrate (New England Biolabs, 
Crawley, UK). Total and phosphorylated protein concentrations of PKBSer473, eEF2 Thr56, 
P70S6K Thr389, 4E-BP1 Thr37/46 and FOXO1a Ser256 were quantified as follows. Fifty 
micrograms of each protein sample (or 15 µl for kinase reactions) was loaded on to a 
7-15 % SDS-PAGE gel (Criterion XT Bis-Tris; Bio-Rad, Hemel Hempstead, UK) for 
electrophoresis at 150 V for ~75 min. Following electroblotting to a PVDF membrane 
(Bio-Rad), proteins were incubated for 1 h with 5 % powdered milk in TBS-T (Tris 
buffered Saline and 0.1 % Tween-20) before incubation overnight with the primary 
antibody at 4°C (New England Biolabs, Herts, UK). The membranes were washed with 
TBS-T and incubated for a further 1 h at room temperature with the HRP-conjugated 
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anti-rabbit secondary antibody (New England Biolabs, Herts, UK), before further 
washing with TBS-T and incubation for 15 min with ECL reagents (enhanced 
chemiluminescence kit, Immunstar; Bio-Rad, Hemel Hempstead, UK).  Blots were 
imaged and quantified using Chemidoc XRS system (BioRad, Hemel Hempstead, UK).  
 
Extraction of RNA 
RNA was extracted from ~20 mg of each muscle sample using 0.5 ml Tri-reagent as 
per the manufacturer’s protocol. Integrity and purity of RNA was assessed by gel 
electrophoresis and luminescence. QuantiTect reverse transcription kit (Qiagen Ltd, 
Crawley, UK) was used for cDNA synthesis and genomic DNA elimination. Real-time 
PCR was performed using SYBR Green supermix (BioRad, Hemel Hempstead, UK) 
and primers (MWG, Ebersberg,Germany) as per Table 2.4. Reverse transcription and 
PCR were conducted using the ICyclerIQ (BioRad, Hemel Hempstead, UK). Primers 
were, in the most part, individually designed and tested previously. 
 
Table 2.4  Gene primers used for real-time PCR. All 5’-3’ 
Gene Sense Anti-sense 
MuRF1 AGTGACCAAGGAGAA CAGTCA  CACCAGCTTTGTGGACTTGT 
MAFBx TCCTGGAAGGGCACTGAC CCATATTCCCAGCTCTCCAG 
C2 subunit CATTGAAAAGGGCGCAATC GCCATATCGTTGTGTTGGTA 
GLUT4 CAGTATGTTGCGGAGGCTAT CCTCGAGTTTCAGGTACTCTT 
Cathepsin L TGAAGAATCAGGGTCAGTGTGG TGAGGCCCAGAGCAGTCTAC 
Ubiquitin GATCTGCCGCAAGTGCTA CAGTCAATGAAA GGGACACT 
GAPDH CTGACCTGCCGTCTAGAAAA GCCAAATTCGTTGTCATACC 
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2.2.5 Calculations  
Fractional synthetic rate of muscle 
The rate of MPS was calculated using the following equation: 
FSR (%.h-1) = (ΔEm/Epx t-1) × 100  
(Nair, Halliday, & Griggs 1988) 
where ΔEm is the change in labelling of muscle protein leucine between two biopsy 
samples, Ep is the mean enrichment over time of the precursor for protein synthesis 
(taken as venous α-KIC 13C2 labelling), and t is the time between biopsies. Venous α-
KIC was chosen to represent the immediate precursor for protein synthesis, i.e. leucyl-
tRNA (Watt et al. 1991).  
 
Arterio-venous AA flux 
Leg protein flux (i.e. breakdown; LPB) was calculated from the arterio-venous dilution 
of D5 phenylalanine and [1,2 13C2]leucine tracers using the following equation: 
LPB = [(Ea/Ev) -1]×Ca x blood flow 
(Bennet et al. 1990a) 
 where Ea and Ev are the values of amino acid labelling at steady state in arterial and 
femoral venous plasma, Ca is the mean concentration in the arterial blood with blood 
flow in ml.100 ml leg-1, adjusted for the haematocrit and leg volume (assessed by 
DEXA).  The net amino acid balance was calculated as the difference in arterial and 
venous concentrations multiplied by the flow. 
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2.3 Statistical analysis 
2.3.1 Sample size calculations 
For healthy volunteer studies a sample size of 8 participants in each group was 
calculated from a formal power calculation, with α set at 0.05 and power at 80 %. The 
data for this calculation was based upon a substantial number of muscle metabolism 
studies of normal healthy young and older men and women conducted by the research 
group. For repeated measures of muscle protein labelling in the same sample, taken 
through the entire extraction and analysis process, the coefficient of variation (CV) is 
~3.8 %. The population CV is ~ 10 %, for young men and women and 12 % for older 
men, thus a common value of 15 % was adopted. The CV of mRNA expression is 
approximately 30 %, and therefore well below the changes in mRNA expression seen 
after a physiological intervention in muscle of up to 4 fold. For western analysis CV are 
approximately 20 % in healthy young and older adults.  
 
A power calculation was again used for the patient study to determine an adequate 
sample size (n = 17). Power was set at 90 % to detect a significant change in TBW and 
LBM as small as 2 % change, with significance set at 5 %. This assumed a standard 
deviation for the measurement of LBM of each patient of at most 1.8 % of body weight, 
although, in practice, it was expected that the standard deviation would be less than 
1.8 %, giving more credence to the estimation of power as being more than 90 %.  
Participants were randomized to receive active drug or placebo after screening using a 
randomization protocol generated by an independent statistician using block 
randomization (blocks length of 4). Drug allocation was concealed until all participants 
had completed the study and data points had been recorded.  
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2.3.2 Data analyses 
Data was analyzed using Prism version 5 (Graphpad, San Diego, CA) and SPSS 
version 14.0, (SPSS Inc.). Tests for normality (Shapiro-Wilk, Kolmogorov-Smirnov & Q-
Q plots) were used to assess whether or not data was distributed in a normal pattern.  
A Gaussian distribution was found for much of the healthy volunteer data and as such 
means ± standard error of the mean (SEM) and parametric tests, specifically t-tests 
and ANOVA with Bonferroni post hoc test, are presented. Significance was assigned at 
P < 0.05 for all data and two-tailed tests have been used throughout, unless specifically 
stated. 
 
For the randomized controlled trial an intention to treat analysis was performed albeit 
limited by missing data where patients were unable to complete the protocol. Tests for 
normality confirmed the data was not distributed in a normal pattern; therefore 
medians, interquartile ranges (IQR) and non-parametric tests were used, specifically 
Mann-Whitney test, Wilcoxon signed ranks test and Pearson Chi-Square test. Survival 
comparisons were made between groups using Kaplan-Meir plots and log rank tests. 
 
Chapter 3 
Randomized placebo controlled trial of thalidomide use in 
patients with cachexia due to oesophageal cancer  
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Over 7,500 individuals are diagnosed with oesophageal cancer in the UK each year 
and only 10 % survive to 5 years beyond diagnosis despite surgical and oncological 
treatments. Profound skeletal muscle wasting is a common feature of the disease 
(despite effective endoscopic management of dysphagia and nutritional 
supplementation) and results in a poorer prognosis (DeWys 1982; Di et al. 2006). 
Established treatments for wasting are limited to supplements, megestrol acetate, and 
corticosteroids. At best these agents may increase adipose tissue, but fail to stimulate 
skeletal muscle synthesis or slow muscle protein breakdown; hence novel treatment 
strategies are required.  
 
Preliminary clinical data suggests thalidomide is an effective treatment in cachexia; 
however, to date there is insufficient evidence to advocate widespread use in 
oesophageal cancer cachexia. This study was designed to test the hypothesis that 
thalidomide increases total body weight and lean body mass in patients with 
oesophageal cancer, over and above body changes seen in patients taking placebo. 
 
3.1 Results 
3.1.1 Patient Flow 
Of 126 patients which were identified as eligible 84 declined entry into the study, 6 
were excluded due to neuropathy or a clinical deterioration, and a further 2 died prior to 
randomization.  Thirty-four patients were randomized to receive thalidomide or placebo. 
Eight patients in the thalidomide arm were able to attend for repeat studies at week six, 
2 of whom had discontinued treatment due to toxicity; a further 2 patients were able to 
tolerate treatment but were too unwell to attend for repeat studies.  The remaining 
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patients withdrew participation due to drug toxicity or disease progression. Sixteen 
patients who received placebo were able to complete the protocol; one patient had died 
unexpectedly in his sleep one week after entry.  
 
 
Figure 3.1 Patient flow 
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disease progression 
or drug toxicity
Not Randomised:
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3.1.2 Baseline demographics 
The groups were well matched in all areas except body composition; the thalidomide 
group was significantly heavier in terms of TBW, LBM and MAMC (Table 3.1).  
 
Table 3.1 Group demographics at baseline. Values are median (IQR) unless count (%) 
denoted by * 
 
Thalidomide 
n = 17 
Placebo 
n = 17 
P 
Sex (M:F)* 15:2 13:4 ns 
Age (y) 68.0 (57.7,80.2) 65.9 (58.9,79.9) ns 
Histology * 
  Adenocarcinoma 
  Squamous Cell 
  Undifferentiated 
 
14 (82.4) 
2 (11.8) 
1 (5.9) 
 
11(64.7) 
4 (23.5) 
2 (11.8 ) 
 
ns 
ns 
ns 
PreviousTreatments * 
  Oesophagectomy 
  Radiotherapy 
  Chemotherapy 
 
4 
4 
5 
 
4 
3 
8 
 
ns 
ns 
ns 
Karnofsky score 70 (60,80) 80 (70,90) ns 
Piper fatigue score 6.0 (3.9,7.8) 4.5 (3.1,5.4) ns 
C-Reactive Protein 31.3 (11.1,46.8) 23.7 (2.8,39.3) ns 
TNFα 3.59 (2.30,5.34) 2.23 (1.83,4.02) ns 
Haemoglobin (g.dl-1) 11.3 (10.2,12.0) 10.1 (9.5,12.5) ns 
Albumin (g.l-1) 32.0 (28.0,36.8) 32.0 (27.5,36.0) ns 
BMI (kg.m-2) 23.1 (19.8,25.2) 19.1 (17.2,20.4) <0.01 
TBW (kg) 64.0 (60.1,72.0) 50.7 (47.0,59.9) <0.01 
LBM (kg) 50.2 (44.7,51.8) 42.2 (39.0,45.8) <0.01 
MAMC (cm) 23.5 (22.4,26.0) 20.1 (19.5,22.1) <0.01 
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3.1.3 Body composition changes 
Over the 6 week study period TBW and LBM did not differ significantly from baseline in 
either study group (Figure 3.2), median change in TBW 0 kg (-0.85, 1.75) and -1 kg (-
3.85, 0.30) for placebo and thalidomide arms respectively. Availability of additional 
MAMC data points failed to show muscle mass changes at 2 or 4 weeks of treatment 
(Figure 3.3). Furthermore there was no difference in TBW or LBM between the 
treatment groups (all P > 0.05). 
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Figure 3.2  Total body weight and lean body mass (LBM) at baseline and after 
treatment with either thalidomide (open diamonds) or placebo (closed triangles) for 6 
weeks.  
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Figure 3.3  Change in mid-arm muscle circumference (MAMC) in patients taking 
thalidomide (open diamonds) or placebo (closed triangles).  
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3.1.4 Metabolic studies  
Resting energy expenditure per kg LBM did not differ significantly between the study 
groups at baseline: Median REE in kcal per Kg LBM per day was 32.8 (28.3, 36.7) and 
33.6 (32.0,37.3) kcal.kg LBM-1.d-1 for patients taking placebo and thalidomide 
respectively (Figure 3.4). Follow up data was available for 13 patients on placebo and 
only 6 patients on thalidomide; the placebo group demonstrated a statistically (but not 
clinically) significant increase from baseline readings (P = 0.02). There was no 
difference from baseline in the thalidomide group. 
 
 
Figure 3.4  Change in resting energy expenditure (REE) in patients taking thalidomide 
(open bars) or placebo (hashed bars). Asterisk denotes significant change compared to 
week 0 values (P < 0.05).  
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3.1.5 Survival  
The mean time to death of all patients was 109 (43.3,174.7) days from the date of 
enrolment. Survival was not affected by group allocation, or whether the patient was 
able to complete the protocol (Figure 3.5). 
 
 
Figure 3.5  Kaplan-Meier survival curves for patients taking either thalidomide (grey 
line) or placebo (black line).   
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3.1.6 Performance indices  
The median Karnofsky score at baseline was 10 points higher in the group given 
placebo (Table 3.2), albeit not reaching statistically significance and scores remained 
relatively constant over the study period. Individual components of the Piper fatigue 
scores did not differ between the groups at baseline. Limited complete data sets were 
available (4 for thalidomide recipients and 10 for placebo recipients) for repeated 
measures analysis. Of those available, only the severity component increased 
significantly in the placebo arm (P = 0.03), whereas affect and sensory components 
increased in the thalidomide arm (P = 0.02 and 0.05 respectively; Figure 3.6). There 
was no significant difference between the groups. 
 
Table 3.2  Karnofsky Scores at baseline and two weekly intervals. Median and IQR 
given. 
 Placebo  Thalidomide  
Baseline 80 (70,90) 70 (60,80) 
Week 2 80 (70,90) 70 (65,90) 
Week 4 80 (70,90) 70 (50,70) 
Week 6 80 (65,80) 60 (45,75) 
 
Figure 3.6  Change in piper fatigue scores over time presented as individual components. Mean ± SEM given; all P > 0.05 when groups compared. 
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3.1.7  Biochemistry  
The concentration of circulating TNFα and CRP did not differ etween the groups at 
baseline, nor did they change with treatment, whereas albumin levels dropped in both 
groups. The reduction was greatest in patients taking thalidomide (35.3 to 31.6 g.l-1, Δ 
3.8 g/L; P = 0.01) and was not significant in the placebo group (31.3 to 29.8 g.l-1, Δ 1.5 
g.l-1; P = 0.12); differences between the groups approached statistical significance (P = 
0.058). 
 
3.1.8  Drug toxicity  
Drug toxicity was experienced by 6 patients (some with multiple adverse events) and, 
in all but one case, resolved upon cessation of treatment (summarized in Table 3.3).  
 
Table 3.3  Drug toxicities 
 
Adverse event Number of cases 
Cutaneous reactions 3 
Headache with vomiting 1 
Neutropenia 1 
Hypersomnolence 1 
Venous thrombo-embolic events  2 
Parasthesia 3 
 
Three patients experienced cutaneous reactions within 1 week of enrolment; 1 patient 
developed a pruritic maculo-papular rash involving the limbs and trunk; a second 
giddiness and a macular non-pruritic rash (Figure 3.7); a third patient developed an 
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eczematous reaction with peri-orbital and limb dermatitis which did not resolve on 
cessation of thalidomide but required oral prednisolone for 8 weeks (Figure 3.8).  
 
One patient experienced severe headaches, nausea and vomiting at 3 weeks, 
resembling raised intracranial pressure but brain CT was normal and symptoms 
resolved on drug withdrawal. Hypersomnolence was reported by one patient who 
required dose reduction to 100 mg nocte. In a further case neutropenia occurred after 4 
weeks of treatment (absolute neutrophil count 0.47 x109.l-1) and resolved within 7 days 
of stopping thalidomide. 
 
Confirmed venous thrombo-embolic events (VTE) occurred in two patients receiving 
the active drug. Bilateral pulmonary emboli where diagnosed on CT pulmonary 
angiography 15 days after commencing therapy in the first patient and a deep vein 
thrombosis was diagnosed 7 days after trial completion in the second.  
 
Three patients developed parasthesia on treatment. One patient developed symptoms 
after 2 weeks of thalidomide, but chose to continue on the background of normal nerve 
conduction studies. On trial completion he elected to take open-labelled thalidomide for 
a further 6 months without evidence of progressive nerve toxicity. Two patients who 
had also elected to take open-labelled thalidomide developed parasthesia after study 
completion. In both cases the patients discontinued thalidomide and experienced 
complete resolution of symptoms.  
 
Chapter 3 
 129 
 
 
 
 
Figure 3.7  Macular rash presenting on the lower limb within 4 days of thalidomide use 
 
Chapter 3 
 130 
Figure 3.8 Eczematous reaction with peri-orbital dermatitis following thalidomide use. 
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3.2 Discussion 
3.2.1 Body Composition changes  
The high attrition rate limited availability of paired body composition data preventing 
conclusions from being drawn as to the efficacy of thalidomide in oesophageal cancer 
cachexia. Although the participants who received placebo did not demonstrate loss of 
TBW and LBM, as anticipated, indeed 7 patients taking placebo gained weight during 
the study period, compared with 2 patients taking thalidomide.  Furthermore, 9 patients 
gained or maintained LBM on placebo. As the thalidomide prescribed cohort had a 
greater BMI (23 vs.19 kg.m-2) and LBM, difference between the groups are unlikely to 
be responsible. It is plausible that the placebo group gained lean tissue due to an 
increase in physical activity (perhaps reflected by the increase in REE), combined with 
an adequate dietary intake, both facilitated by the positive psychological effects of 
study participation and regular dietetic support. In contrast patients taking thalidomide 
were less able to experience this psychological effect or indeed drug benefit due to 
drug related toxicity. Alternatively, these findings may simply reflect a type 1 error in a 
small sample.  
 
3.2.2  Functional indices 
Despite a greater LBM, participants randomized to the thalidomide arm had a lower 
Karnofsky score at baseline (median 70 versus 80), which may have contributed to the 
higher morbidity in patients receiving thalidomide. During the course of the study 
performances indices fell in the thalidomide group but it is not possible to dissect out 
how much of this decline in well-being is due to disease progression compared with 
that due to thalidomide related side-effects, bar commenting on the relative stability of 
scores within the placebo arm. The number of participants recruited was determined by 
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the primary end-points rather than functional outcome measures per se and so the 
sample is likely to be too small to accurately comment, particularly as so few 
participants were able to complete the protocol in the thalidomide group.  
 
Piper fatigue questionnaire data demonstrated an increase in fatigue in both groups 
over the 6 week study period, reflecting the declining health of participants. Scores for 
severity indicate the interference of fatigue upon normal activities, such as ability to 
work or socialise; affect describes the degree to which the patient finds fatigue 
unpleasant and abnormal; energy levels are reflected by the sensory component and 
cognitive functions are indicated by mood scores. The increase in fatigue severity in 
both groups suggests the symptom is disease related rather than treatment, whereas 
affect and sensory components appear to be specific adverse effects of thalidomide 
treatment. Entry into the study is a confounding factor upon the mood component and 
likely to give falsely low values at baseline for all participants; as the study progressed 
mood also deteriorated in the placebo arm but not in the thalidomide arm. 
 
3.2.3  Drug tolerability 
Differences between the groups could account for the excess of adverse events seen 
on treatment; however survival beyond randomization and serological indices did not 
differ between the groups at baseline. Over the treatment period, serological 
parameters deteriorated in patients taking thalidomide reflecting either the poor drug 
tolerance or general deterioration due to disease. Nevertheless, the drug toxicity profile 
experienced by trial participants is widely reported; adverse events of thalidomide are 
multi-systemic extending beyond its notorious teratogenicity (Table 3.4). 
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Hypersomnolence is the most common adverse effect of thalidomide therapy. The 
dose-responsive effect is mediated through the diencephalic sleep centers within the 
brain and results in increased REM sleep without respiratory depression (Kanbayashi 
et al. 1999). Severe somnolence requiring drug reduction was only experienced in one 
study patient, possibly due to night time dosing or lack of patient reporting, as many 
patients with end-stage malignancy experience sleep disturbances and insomnia and 
find drugs with sedative side-effects particularly helpful.  
 
Dermatological adverse effects of thalidomide were not so well tolerated and required 
drug withdrawal in 3 patients. Pruritis and rashes are common, affecting up to 50 % of 
thalidomide users (Dimopoulos & Eleutherakis-Papaiakovou 2004). Most skin rashes 
are vesicular, mobilliform, maculopapular or non-specific dermatitis and resolve on 
discontinuation of the drug, allowing re-introduction at a lower dose if necessary. 
Rarely more serious dermatological reactions can occur; erythroderma (Hall et al. 
2003), toxic epidermal necrolysis (Rajkumar, Gertz, & Witzig 2000) and Steven-
Johnson reactions (Clark et al. 2001) have been reported. High-dose thalidomide 
combined with dexamethasone results in a greater incidence of dermatological toxicity, 
and may increase the risk of serious reactions occurring (Hall et al. 2003). 
 
Co-administration of dexamethasone and thalidomide is also associated with a higher 
incidence of VTE (Dimopoulos & Eleutherakis-Papaiakovou 2004; Ikhlaque et al. 
2006), compared with thalidomide monotherapy which carries a 1 - 5 % risk (Bennett et 
al. 2006). Neither of the participants who had a diagnosed VTE were taking 
dexathasone; however malignancy independently confers a 4-fold increase in VTE risk 
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(Heit et al. 2000). Thus it is not possible to directly attribute these events solely to 
thalidomide use. 
 
Table 3.4  Recognized adverse events associated with thalidomide use. 
Neuropathic Headache 
Peripheral neuropathy 
Sedation/Somnolence 
Asthenia 
Depression/Mood Changes 
Postural tremors 
Fever 
Dermatological Rashes 
Pruritis 
Alopecia 
Dry skin 
Endocrine Hypothyroidism 
Gastrointestinal Nausea/Vomiting 
Constipation 
xerostomia 
Cardiovascular Thrombosis 
Hypotension 
Oedema 
Bradycardia 
Haematological Neutrapenia 
Thrombocytopenia 
Thromboembolic events 
Genitourinary Impotence 
Teratogenicity 
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 Peripheral nerve toxicity caused by thalidomide was not seen during the study period 
as nerve damage is dose-dependent, requiring cumulative doses of ~50 g before onset 
of mild symptoms (Fullerton & O'Sullivan 1968), whereas the total cumulative dose at 
study completion was 8.4 g. Patients were offered open-labelled thalidomide at the end 
of the study, but none lived long enough to encounter dose-related side-effects. 
Nevertheless parasthesia was experienced below this 50 g threshold in patients with 
normal nerve conduction studies.  
 
Other studies evaluating the efficacy of thalidomide in cachexia have shown more 
promising outcomes although risk/benefit ratios remain high. Gordon et al. 
demonstrated benefit over placebo in patients with pancreatic cancer cachexia in which 
7 (28 %) patients were withdrawn due adverse events (Gordon et al. 2005). Similarly 
patients with HIV wasting disease who were given either 100 mg or 200 mg of 
thalidomide or placebo experienced adverse events leading to drug withdrawal in 22 %, 
37 % and 14 % of participants respectively. Patients given the 100 mg dose did better 
in terms of total weight and fat free mass gain than those given 200 mg (Kaplan et al. 
2000). Thus tolerability may be increased by commencing patients on low doses 
initially and escalating as tolerated.  
 
3.2.4  Future research questions 
Whether thalidomide would be better tolerated in patients with less advanced disease, 
at lower doses or as an adjunct to chemotherapy remains open for investigation. 
Thalidomide has been shown to delay the progression of some solid tumours (Singhal 
& Mehta 2002; Gordinier et al. 2007) and improve the tolerability of GI toxic 
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chemotherapy agents such as Irinotecan (Govindarajan et al. 2000). Therefore it is 
possible that thalidomide may enable preservation of lean body mass during 
chemotherapy, justifying further clinical trials of thalidomide in oesophageal cancer 
cachexia.  
 
3.2.5  Conclusions 
In conclusion this study demonstrates that thalidomide confers no benefit over placebo 
to patients with end-stage oesophageal cancer, predominantly due to drug toxicity. 
Thirty-five percent of patients given active treatment were unable to continue taking the 
drug due to side-effects which, when combined with disease-related morbidity, lead to 
insufficient data for meaningful analysis of body composition end-points.   
Chapter 4  
Overcoming anabolic blunting with supraphysiological insulin 
availability 
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The blunted response of MPS to AA with ageing appears to contribute to the 
pathophysiology of sarcopenia, although the mechanism by which this occurs is not 
known. Insulin resistance, commonly present with ageing, affects the P-I-3K pathway 
and may influence activation of nutrient sensing proteins, including mTOR, thus may 
contribute to anabolic blunting. This chapter addresses the effects of administering 
insulin, with the aim of achieving supraphysiological plasma concentrations, upon AA 
driven MPS, in an attempt to overcome anabolic blunting.  
 
4.1 Study aims and hypotheses  
Taking into account the work of other investigators, a protocol was designed to address 
two specific aims; first, to determine whether anabolic blunting could be overcome by 
increasing the availability of insulin, and second, to determine the PKB-mTOR 
signalling responses under these conditions. Thus the following hypotheses could be 
tested: H1 insulin resistance underpins age related anabolic blunting; H2 Rates of 
protein synthesis in older adults can be restored to that of the young by the 
administration of insulin; H3 Phosphorylation of anabolic signalling proteins, specifically 
mTOR, 4E-BP1 and P70S6K, in response to AA do not differ between young and older 
volunteers in whom supraphysiological insulin concentrations have been administered.  
 
4.2 Study protocol  
 Figure 4.1, which is a modified version of Figure 2.7, duplicated here for ease of 
reference, describes the protocol.  A full description of recruitment, screening and study 
protocols are given in Chapter 2. 
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Figure  4.1.  Protocol to assess the effects of high dose insulin and intravenous AA 
feeding upon muscle protein synthesis, in young and older healthy volunteers. 
 
 
-1         0            1              2              3              4               5
Time (h)
Muscle biopsyBlood sample
[1,213C2]leucine
↑ Insulin Clamp
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4.3 Results 
4.3.1 Participants 
Initially 8 young and 11 older healthy volunteers were recruited and completed the 
screening protocol: 15 completed the study protocol. All volunteers were deemed 
eligible to participate at screening and had no biochemical or haematological blood 
abnormalities. Of the two older volunteers who failed to complete the protocol, one 
failed to attend on the study day and one had an adverse event during the study; both 
young volunteers failed to attend on their study days. Data from these four individuals 
have been excluded from subsequent analysis.  
 
The mean age of the young (n = 6) and older (n = 9) participants were 22.3 ± 1.7 and 
66.0 ± 1.7 y respectively. In the young group there were equal numbers of male and 
female participants; there was one additional male participant in the older group. 
Participant characteristics are given in Table 4.1. 
 
Body composition did not differ between the age groups, (for both groups mean BMI 
was ~24 kg.m-2 and LBM was ~48 kg). Each group demonstrated clustering of LBM 
values reflecting sexual dimorphism (Figure 4.2). The mean plasma concentrations of 
CRP at baseline appear to be higher in the older volunteers (6.4 ± 2.6 vs. 2.2 ± 0.3 
μg.ml-1) but this does not reach statistical significance (P = 0.36). 
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Table 4.1  Characteristics of participants. Mean ± SEM.  
 Young Older P 
n 6 9  
Age (y) 22.3 ± 1.7 66.0 ± 1.7 <0.01 
M:F 3:3 5:4 ns 
Height (m) 1.7 ± 0.5 1.7 ± 0.0 ns 
Weight (kg) 72.7 ± 7.8 67.7 ± 2.9 ns 
BMI (kg.m-2) 24.6 ± 1.7 24.1 ± 0.6 ns 
LBM (kg) 47.8 ± 6.8 47.5 ± 3.1 ns 
ALBM (kg) 23.3 ± 3.6 22.8 ± 1.8 ns 
RSMI (kg.m-2) 7.8 ± 0.8 8.0 ± 0.5 ns  
CRP (μg.ml-1) 2.2 ± 0.3 6.4 ± 2.6 ns 
  
  
 
Figure 4.2  Scatter plot of lean body mass demonstrating sexual dimorphism.  
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4.3.2 Insulin sensitivity 
There was no evidence of diabetes mellitus or insulin resistance in any of the 
participants at baseline. Basal insulin sensitivity (as determined by blood insulin 
concentration or HOMA-IR) did not differ between the groups (Table 4.2). Glucose 
requirements in order to maintain plasma glucose between 4.5 and 5.0 mmol.l-1 during 
the hyperinsulinaemic euglycaemic clamp were also similar, although this data could 
not be used as a direct indicator for insulin sensitivity due to the accompanying AA 
infusion.   
 
Table 4.2 Insulin sensitivity and glucose requirements; mean ± SEM 
 Young  Older  P 
PA Insulin  
(μIU.ml-1) 4.4 ± 0.7 6.7 ± 1.6 ns 
PA Glucose 
(mmol.l-1) 4.7 ± 0.1 5.1 ± 0.3 ns  
HOMA-IR  1.0 ± 1.2 0.9 ± 0.1 ns 
Glucose 
requirement (g) 750 ± 108 810 ± 114 ns 
 
 
4.3.3 Amino acid concentrations 
Total quantities of essential and BCAA concentrations did not differ significantly 
between the younger and older age groups in the postabsorptive state. Of the 
individual AA only histidine and isoleucine concentrations differed between the groups 
– both were significantly greater in the young (Table 4.3).  
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Table 4.3  Basal venous amino acid concentrations in young and older healthy 
volunteers. Mean ± SEM given, all values in nmol.l-1.  
 
  Young Older P 
Alanine 289.8 ± 28.0 303.3 ± 11.9 ns 
Arginine 80.4 ± 3.6 75.2 ± 6.9 ns 
Asparginine 57.4 ± 3.7 48.9 ± 2.9 ns 
Aspartic Acid 11.9 ± 2.0 17.8 ± 3.6 ns 
Cysteine 20.0 ± 5.5 28.7 ± 8.1 ns 
Glutamic acid 94.2 ± 14.7 112.3 ± 28.3 ns 
Glutamine 332.2 ± 48.7 352.3 ± 44.6 ns 
Glycine 206.6 ± 17.0 197.3 ± 14.3 ns 
Histidine 81.2 ± 4.8 67.4 ± 3.7 0.04 
Isoleucine 61.9 ± 5.4 45.5 ± 2.8 0.01 
Leucine 140.6 ± 12.6 122.5 ± 7.5 ns 
Lysine 165.6 ± 14.1 177.7 ± 11.0 ns 
Methionine 20.1± 2.1 19.7 ± 2.9 ns 
Phenylalanine 57.1 ± 4.3 52.4 ± 3.2 ns 
Proline 191.9 ± 13.2 146.2 ± 18.9 ns 
Serine 95.4 ± 9.1 89.8 ± 10.6 ns 
Threonine 117.3 ± 11.3 106.3 ± 6.9 ns 
Tryptophan 52.1 ± 5.1 35.8 ± 6.2 ns 
Tyrosine 54.0 ± 4.7 59.5 ± 4.1 ns 
Valine 211.2 ± 15.3 197.5 ± 14.1 ns 
Total BCAA 413.7 ± 32.3 365.6 ± 23.9 ns 
Total EAA 988.2 ± 63.5 899.9 ± 46.1 ns 
Total AA 2131 ± 45.6 2121 ± 164.0 ns 
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4.3.4 Hyperinsulinaemic euglycaemic clamp 
During the clamped phase of the study the mean insulin concentration for both groups 
exceeded the target of 100 μIU.ml-1 and differed significantly from PA values (both P < 
0.001), although concentrations differed between the young and older participants 
(mean concentrations 107.4 ± 4.4 and 133.0 ± 5.5 μIU.ml-1 respectively; P = 0.01).  
Plasma insulin availability was maintained in all groups throughout the 2.5 h feeding 
period (Figure 4.3) (ANOVA repeated measures, all P > 0.05). Mean plasma glucose 
concentrations differed: the concentrations were lower in the young participants, albeit 
not to a clinically significant degree (4.6 ± 0.1 and 5.1 ± 0.1 mmol.L-1; P < 0.01). 
 
One older participant had an adverse reaction to the clamp which was consistent with 
octreotide intolerance and occurred within 4 min of commencing the clamp infusions. 
Facial flushing and disorientation developed with erythematous tracking overlying the 
infusion site. On stopping the infusion there were no further ill effects. Four volunteers 
reported diarrhoea within 12 to 24 h of the clamp which resolved spontaneously, in 
keeping with steatorrhoea due to octreotide induced fat malabsorption. In subsequent 
studies pancreatic enzymes were offered to participants to take prior to meals within 12 
h of the clamp, which markedly reduced these symptoms.  
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Figure 4.3  Plasma insulin (left axis; solid line) and whole blood glucose (right axis; 
dashed line) concentrations over time for young (filled triangles) and older (open 
squares) participants. All mean ± SEM (error bars not seen are within symbols). 
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4.3.5 Plasma AA concentrations 
During the fed period, venous plasma AA concentrations were elevated in all groups, 
albeit substantially less than anticipated. Plasma BCAA (leucine, isoleucine and valine) 
and total EAA concentrations were significantly elevated over fasting concentrations 
and did not differ between young and older participants (all P < 0.05, Mann Whitney 
one-tailed test; Figure 4.4).  Area under the curve data calculated above basal 
concentrations for leucine and EAA were also similar for all participants (Figure 4.5).   
 
Plasma enrichment of [1,213C2] α-keto-isocaproate was maintained at steady state 
throughout both periods and did not differ between participants. See Appendix 6. 
 
 
Figure 4.4  Plasma concentrations of individual branched chain amino acids and total essential amino acids (EAA) during postabsorptive and fed 
periods for young (solid line and filled triangles) and older (dashed line and open squares) healthy volunteers. Error bars not shown are hidden within 
symbols. 
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Figure 4.5  Area under the curve above postabsorptive concentrations for plasma 
leucine and essential amino acids (EAA) during fed periods. 
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4.3.6 Muscle Protein Synthesis  
In the PA state FSR did not differ between young and older volunteers: 0.040 ± 0.008 
and 0.047 ± 0.004 %.h-1, respectively (P = 0.4). FSR values increased significantly in 
both groups following insulin and AA administration but between group values did not 
differ (young: 0.070 ± 0.006 and older: 0.069 ± 0.010 %.h-1; both P < 0.05 compared 
with respective PA values; Figure 4.6).  
 
 
Figure 4.6 The effect of postabsorptive (empty bars) and fed conditions with 
supraphysiological insulin concentrations (hashed bars) upon FSR in young and older 
adults. Asterisks indicate a significant increase from PA values; P < 0.05.  
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4.3.7 Anabolic signalling pathways 
Western Blotting of total and phosphorylated proteins involved in the PKB and mTOR 
pathways was performed on muscle samples taken before and after the simultaneous 
AA and insulin infusions.  
 
Phosphorylation of PKB at Thr308 was increased in both young and older participants, 
although the response to AA infusion and hyperinsulinaemic clamp conditions was 
significantly greater in the young (P < 0.05; Figure 4.7).  
 
 
Figure 4.7  Phosphorylation status of PKB at Thr308 relative to total protein under 
postabsorptive (open bars) and fed (hashed bars) conditions. Asterisks denote 
significant difference from PA phosphorylation state; dagger indicates significant 
difference from young data; P < 0.05. 
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In both young and older groups GSK 3β inactivation, as determined by increased 
phosphorylation at Ser9, was increased by hyperinsulinaemic hyperaminoacidaemic 
conditions.  Again, the increase was significantly greater in the young (P < 0.05; Figure 
4.8).  
 
 
Figure 4.8  Phosphorylation of GSK3β at Ser9 under postabsorptive (open bars)and 
fed (hashed bars) conditions. Asterisks denote significant difference from PA 
phosphorylation state; dagger indicates significant difference from young data; P < 
0.05. 
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The proportion of phosphorylated eEF2 at Thr56 did not differ with feeding or between 
young and older participants (Figure 4.9, all P > 0.05). 
 
 
 
 
 
Figure 4.9  Phosphorylation of eEF2 at Thr56 relative to total eEF2 under 
postabsorptive (open bars) and fed (hashed bars) conditions for young and older 
participants. 
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mTOR phosphorylation at Ser2448 did not differ between the young and older adults 
when measured following either the PA or fed phase nor was there a difference 
between age groups (Figure 4.10).  
 
 
 
 
Figure 4.10  Phosphorylation status of mTOR at Ser2448 relative to total protein under 
postabsorptive (open bars) and fed (hashed  bars) conditions. 
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Under PA conditions phosphorylation of downstream substrates of mTOR, namely 
P70S6K at Ser389 and 4E-BP1 at Thr36-46, were also similar regardless of age. 
Phosphorylation of both proteins increased significantly in response to fed conditions 
(Figures 4.11 and 4.12) but to a greater extent in the young (P < 0.05). eIF4G – eIF4E 
association did not change in either group in response to hyperinsulinaemia and AA 
feeding (Figure 4.13). 
 
 
Figure 4.11  Phosphorylation status of P70S6K at Thr389 relative to total protein with 
postabsorptive (open bars) and fed (hashed bars) conditions. Significant change from 
PA given by asterisks; significant difference from young data indicated by dagger; P < 
0.05.  
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Figure 4.12  Phosphorylation of 4E-BP1 at Thr37/46 relative to total protein under 
postabsorptive (empty bars) and fed (hashed bars) conditions. Significant change from 
PA given by asterisks; significant difference from young data indicated by dagger; P < 
0.05. 
 
Figure 4.13  Association of eIF4G and eIF4E relative to eIF4E recovery before (open 
bars) and after hyperinsulinaemia and AA feeding (hashed bars) in young and older 
participants.  
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The proportion of phosphorylated eIF2α protein at Ser51 was similar between young 
and older participants following the PA period (P = 0.15). Phosphorylation decreased 
significantly in response to hyperinsulinaemia and AA feeding in the young (P < 0.05), 
but not in the older group (Figure 4.14).  
 
 
 
Figure 4.14  Proportion of phosphorylated eIF2α following postabsorptive (open bars) 
and fed periods (hashed bars). Significant change with fed conditions indicated by 
asterisk; P < 0.05.  
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4.3.8 Proteolytic markers 
Administration of supraphysiological doses of insulin and AA reduced expression of 
MAFbx mRNA in both the young and older volunteers by ~25 % (Figure 4.15). The 
same conditions resulted in a similar reduction of MuRF-1 mRNA expression in muscle 
from older adults, but expression was increased by 25 % in the young (Figure 4.16). 
For older participants changes in MAFbx and MuRF-1 achieved significance (both P < 
0.02), although neither was significant in the young. When change in expression of 
MAFbx and MuRF-1 were compared between young and older participants, no 
significant difference was seen.   
 
Figure 4.15  Quantification of MAFbx mRNA (normalized to PA values, arbitrarily given 
here as empty bars) in response to hyperinsulinaemia and AA (hashed bars) for young 
and older participants. Mean ± SEM given; significant reduction from PA values 
indicated by asterisk (P < 0.02). 
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Figure 4.16  Quantification of MuRF-1 mRNA (normalized to PA values, arbitrarily 
given here as empty bars) in response to hyperinsulinaemia and AA (hashed bars) for 
young and older participants. Mean ± SEM given; significant reduction from PA values 
indicated by asterisk (P < 0.02). 
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4.4 Discussion 
4.4.1 Participants 
As volunteers were recruited in response to advertisements, there was no selection 
process per se, yet body composition data for young and older participants were well 
matched by random selection. This appears to contradict the concept of sarcopenia; 
however the data reflect a very sample size of active older adults rather than a cross 
section of the whole population. Nevertheless differences are seen in signalling 
responses to feeding which suggests that the underlying physiological changes 
associated with sarcopenia are still present.  
 
4.4.2 Plasma branched chain amino acid availability  
Dose-response data for plasma BCAA following a mixed AA intravenous infusion under 
hyperinsulinaemic conditions was not available at the outset of the study, therefore an 
estimate was used based upon data from Cuthbertson et al. (Cuthbertson et al. 2005). 
The dose chosen was comparable to a 40 g EAA oral feed. Lower plasma 
concentrations of AA were anticipated due to the high target insulin concentrations, as 
insulin enhances AA oxidation and gluconeogenesis and suppresses protein 
breakdown. The degree to which this was offset by the increased bioavailability of AA 
when given intravenously when compared with oral administration was unknown. 
Nevertheless the plasma BCAA concentrations observed during the study equated to a 
lower dose than expected, i.e. ~ 50 % increase in plasma AA. The area under the 
curve values above basal for leucine were equivalent to a 2.5 g oral dose of EAA. 
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A higher rate of AA infusion may have produced target plasma doses; although these 
may not have been sustained. This is demonstrated by the reduction of leucine and 
isoleucine concentrations to basal values over the 2.5 h administration period, despite 
a continuous rate of infusion. Total EAA concentrations remained constant which 
suggests that either leucine and isoleucine were preferentially metabolised or that the 
proportion of these BCAA within the AA feed were insufficiently matched to utilization. 
As the proportions of leucine and isoleucine in PA plasma and the AA infusion did not 
differ, preferential metabolism is likely to be responsible for the accelerated removal of 
these AA from the plasma, whether by oxidization, glyconeogenesis or muscle protein 
synthesis. 
 
4.4.3 Changes in FSR in response to AA feeding and high insulin availability 
FSR increased, as expected, following AA feeding but there was no difference between 
values for young and older participants; however this is not inconsistent with anabolic 
blunting data. Other workers have shown no difference with senescence following low 
dose feeds (e.g. 2.5 g EAA given orally) but blunting at higher plasma AA 
concentrations (Cuthbertson et al. 2005). FSR values in Cuthbertson’s study were 
marginally lower than those seen here, despite employing the same tracer and 
analytical methodology, but this may be readily explained as measurements were 
made over a 3 h period, rather than 2.5 h. The maximal synthetic response to feeding 
occurs within the first 2.5 h after a meal (Bohe et al. 2001). Thus the average FSR 
taken over 3 h includes a period of PA synthesis and will therefore be lower than when 
measured over a 2.5 h absorptive period.  It is unlikely that the differing values result 
from the addition of high dose insulin administration, as others have shown that insulin 
has no additive effect upon MPS (Greenhaff et al. 2008).  
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It is unknown whether the threshold for maximal stimulation of MPS occurs earlier in 
older adults than in the young or whether at higher AA doses the muscle reaches this 
threshold more rapidly (Rennie, Bohe, & Wolfe 2002). A shorter window of MPS in 
response to feeding would account for differences seen in the rates of muscle protein 
synthesis in the young and older participants by other investigators (Cuthbertson et al. 
2005; Welle et al. 1993; Balagopal et al. 1997) i.e. absorptive FSR values from older 
individuals taken over 3 h or longer reflect a greater proportion of time points during 
which synthesis has reverted to postabsorptive rates. Although this concept is not new, 
first put forward by Price et al. (Price et al. 1994), it is unknown whether this theoretical 
tachyphylaxis is driven by chronological or dose-related thresholds.   
 
4.4.4 Blunted anabolic signalling protein responses to AA in older adults 
The phosphorylation responses of signalling proteins involved in the sensing and 
signalling of AA were diminished in the older group when compared to that of the 
young, even though no difference was seen in FSR between the groups. This is in 
keeping with other published data (Cuthbertson et al. 2005). The degree of 
phosphorylation of mTOR, p70S6K and 4E-BP1, relative to total concentration, 
following a 10 g EAA feed, was higher in young men when compared with their older 
counterparts. Leaving aside the mTOR data, this suggests that a blunted signalling 
response to AA is not overcome by supraphysiological insulin concentrations, as 4E-
BP1 and p70S6K activation in response to AA was diminished in the older participants 
of the present study. Furthermore the high insulin availability did not elicit the same 
degree of PKB and GSK3ß phosphorylation in the older adults: either there is a greater 
resistance to phosphorylation in older adults or that high circulating insulin 
concentrations in the blood are unable to overcome any up-stream signalling defects 
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due to insulin resistance. The differences seen in PKB and GSK3ß activation between 
the two age groups support the suggestion that anabolic defects in older human beings 
stem from aberrant insulin signalling rather than a direct problem with AA signalling.  
 
Another group, assessing the effects of hyperinsulinaemia and hyperaminoacidaemia 
upon protein synthesis and anabolic signalling, were unable to demonstrate significant 
differences in PKB, mTOR or 4E-BP1 phosphorylation between young and older 
adults, although FSR responses were blunted in the older participants (Guillet et al. 
2004a).  In the fed phase of this study plasma BCAA concentrations differed 
significantly between the young and older participants (~1.8 fold and ~2.7 fold increase 
respectively), potentially accounting for the similar signalling responses. The rise in 
insulin concentrations also differed between the groups (44 and 63 μIU.ml-1) but did not 
reach significance. However p70S6K phosphorylation rose less in the older group and 
PKB and mTOR phosphorylation changes with feeding were less pronounced than 
seen in the young (again failing to reach statistical significance) in concordance with 
the data presented here.  
 
P70S6K is relevant to insulin resistance of glucose metabolism as it appears to 
suppress insulin signalling by negative feedback through IRS-1, such that AA have an 
inhibitory effect upon insulin signalling through PI-3K (Patti 1999). Animal data further 
supports this argument: p70S6K knock-out mice remain insulin sensitive when exposed 
to a high fat diet, unlike their wild-type controls, and demonstrate enhanced PKB 
phosphorylation in response to insulin administration (Um et al. 2004). Thus in older 
subjects, in whom p70S6K phosphorylation is reduced, PKB activation by insulin ought 
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to be enhanced; in the present study this was not the case, reflecting the likelihood that 
this is a gross simplification. 
 
mTOR phosphorylation at Ser2448 did not differ with feeding or between the young 
and older groups, potentially explained by the timing of the biopsy. It is possible that 
mTOR phosphorylation is returning to basal levels 2.5 h after the onset of the feed but 
down-stream substrates of the kinase remain up-regulated. Alternatively the high 
insulin concentrations may have acted as a direct inhibitor of mTOR phosphorylation, 
or precipitated cellular re-distribution of mTOR to the nucleus preventing its 
phosphorylation by activated PKB.  
 
The phosphorylation status of down-stream substrates fails to add any further light to 
the mTOR picture, as although p70S6K and 4E-BP1 phosphorylation were up-
regulated, the phosphorylation of eEF2, an elongation factor which is ordinarily 
inhibited by mTOR, remained unchanged. Although it is possible that eEF2, like mTOR, 
may be temporally responsive and thus its phosphorylation status may have returned 
to PA values at the time point sampled.  
 
Alternatively, it is plausible that kinase activity is not dependent upon phosphorylation 
status of mTOR at Ser2448. The phosphorylation site was Ser2448 was chosen for two 
reasons: i) PKB induces phosphorylation at this site and at Thr2446 which lies adjacent 
to it (Hay & Sonenberg 2004), and ii) insulin has also been shown to specifically induce 
phosphorylation at Ser2448 (Sekulic et al. 2000); nevertheless the significance of 
phosphorylation at these sites, in terms of mTOR activation, is unclear. Experiments 
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using rapamycin to inhibit activation of mTOR suggest that disruption of the mTOR-
Raptor dephosphorylation per se. Other data supports this suggestion: replacement of 
Thr2446 and Ser2448 residues with alanine does not appear to alter mTOR activity 
(Sekulic et al. 2000). 
 
Recently other workers (Adegoke et al. 2009; Fujita et al. 2009b) have shown this 
pattern of signalling responses to hyperinsulinaemic clamp conditions. In the young 
men studied by Adegoke et al., phosphorylation of PKB, P70S6K1 and 4EBP1 were 
increased after 2h of hyperinsulinaemic hyperaminoacidaemic and hyperglycaemic 
clamp conditions, but phosphorylation of mTOR Ser 2448 did not differ significantly 
from basal values. These authors also suggest that Raptor binding may explain the 
apparent mTOR activation without expected changes in phosphorylation status. 
Whereas Fujita et al., who measured responses to supraphysiological insulin 
availability at 3 h suggest phosphorylation of mTOR may have occurred at an earlier 
time point and returned to basal levels at the time sampled. 
 
4.4.5 Future research questions 
In order to fully address the aims of this study, i.e. whether hyperinsulinaemia 
overcomes sarcopenic anabolic blunting of protein synthesis, subjects would need to 
receive higher doses of AA to double plasma AA concentrations, ideally with real-time 
plasma AA analysis.  A control arm, of feeding with insulin clamped at PA 
concentrations, would also be useful.  However a modified study has not been carried 
out as the signalling data suggests that administration of supra-physiological insulin 
doses does not overcome anabolic blunting in older human beings.  
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Further important areas for research which need to be addressed are the time course 
of anabolic responses to AA and whether AA pharmacokinetics differ between young 
and older human beings. Such data would not only provide information about the 
optimum protein content and timings of meals for maximum anabolism, but also help to 
unravel the activation time course and role of mTOR, PKB, p70S6K and their 
substrates in the sensing and signalling of AA stimulated protein synthesis.  
 
4.4.6 Conclusions 
In conclusion, the specific aims of this study were not met as target plasma BCAA 
concentrations (i.e. doubling of PA values) were not achieved, probably due to the 
hyperinsulinaemia; however the data collected is novel and adds to the existing 
literature on anabolic blunting in older adults. The study confirms that AA feeding 
initiates an anabolic response in skeletal muscle and, following a low dose AA feed, the 
synthetic response does not differ between the young and older healthy volunteers, yet 
key anabolic signalling responses to AA are blunted in older adults.  
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The inhibitory activity of insulin upon both muscle and whole body protein breakdown 
has been demonstrated in young healthy volunteers (Flakoll et al. 1989; Denne et al. 
1991). When the responses of whole body protein turnover are compared between 
young and older subjects, it appears that, at equivalent insulin and amino acid 
concentrations, rates of protein breakdown are higher in older subjects (Guillet et al. 
2004b; Boirie et al. 2001). The proposition that this may also be true for muscle protein 
has never been tested. Thus, this chapter specifically examines the effects of insulin 
upon leg protein turnover, on the assumption that leg is mainly muscle, in young and 
older human beings, to test the hypothesis that the effects of insulin upon leg 
proteolysis are blunted with healthy senescence.  
 
5.1 Study protocol  
The study protocol, approved by University of Nottingham Medical School Research 
Ethics Committee (Ref G/4/2004), is detailed in Figure 5.1 (this is a duplicate of Figure 
2.8 for ease of reference). A detailed account of recruitment, screening and study 
protocols are given in Chapter 2.  
 
As constant AA availability and tight insulin control was required for this protocol, clamp 
development work was carried out before commencing the tracer studies, with prior 
approval from the ethics committee.  Eight volunteers participated in the development 
phase, which involved octreotide, insulin, AA and dextrose infusions over 3 h with 
arterialized-venous blood sampling at 5 min intervals. Insulin and AA infusion protocols 
were modified to consistently achieve target plasma insulin and AA concentrations. 
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Figure 5.1  Protocol to assess leg proteolysis at plasma insulin concentrations of ~ 5 
and ~ 15 μIU.ml-1 in young and older healthy volunteers. Arterialized-venous blood (A) 
was collected at ~ 5 min intervals to monitor blood glucose concentrations infusions. 
Paired samples of arterialized-venous and femoral vein blood (A and V) were collected 
at baseline and 20 minute intervals through the last hour of each clamp period (small 
arrows), preceded by doppler blood flow measurements (rectangles). Muscle biopsies 
are indicated by large arrows. 
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5.2 Results 
5.2.1 Participant characteristics 
Eight young and 8 older participants, of which 4 of each group were women, were 
successfully screened and completed the study protocol. Participants were ages 24.5 ± 
1.8 and 65.0 ± 1.3 y respectively (all data presented are mean ± SEM, unless 
specified).  
 
C-reactive protein was within the normal range for all healthy volunteers and did not 
differ between the young and older participants. Basal plasma AA concentrations were 
also similar and are given in Table 5.1. 
 
Both groups were of similar total body weight (young: 71.1 ± 5.0 and older: 73.1 ± 3.3 
kg) but the older participants had a greater BMI (26.3 ± 0.4 compared with 23.9 ± 0.9; 
P = 0.03) with equal amounts of lean tissue when normalized for height (Table 5.2).  
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Table 5.1   Basal AA concentrations for young and older participants. All values mean ± 
SEM expressed in mmol.l-1; intergroup t-test analysis for each AA, all P > 0.05. 
 
 Young Older 
Alanine 264.7 ± 22.8 283.8 ± 47.8 
Arginine 74.2 ± 5.0 110.9 ± 33.2 
Asparginine 72.2 ± 3.7 76.2 ± 4.8 
Aspartic Acid 5.4 ± 0.8 13.8  ± 7.5 
Cysteine 36.7 ± 8.0 48.9  ± 5.5 
Glutamine  441.9 ± 35.3 433.7 ± 27.9 
Glutamic acid 21.8 ± 4.2 33.3  ± 13.6 
Glycine 236.1 ± 50.6 223.0 ± 15.6 
Histidine 55.0 ± 12.1 75.5 ± 4.1 
Isoleucine 50.0 ± 4.0 53.0 ± 3.5 
Leucine 113.4 ± 11.5 114.2 ± 8.2 
Lysine 135.5 ± 17.1 177.8 ± 11.4 
Methionine 27.4 ± 3.1 28.9 ± 3.3 
Phenylalanine 51.5 ± 4.4 56.2 ± 2.8 
Proline 168.1 ± 27.5 139.7 ± 14.0 
Serine 102.4 ± 14.5 87.3 ± 6.0 
Threonine 116.8 ± 12.1 113.6 ± 4.6 
Tryptophan 66.5 ± 18.7 52.4 ± 8.3 
Tyrosine 58.5 ± 10.9 62.3 ± 4.0 
Valine 199.8 ± 11.7 208.7 ± 13.1 
Total BCAA 414.8 ± 28.8 432.1 ± 26.4 
Total EAA 890.2 ± 46.0 991.3 ± 51.2 
Total AA 2286.7 ± 176.4 2425.6 ± 70.0 
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5.2.2 Insulin sensitivity 
Basal plasma insulin concentrations were significantly higher in the young participants 
(6.0 ± 0.5 µIU.ml-1 compared with 4.2 ± 0.5 µIU.ml-1; P = 0.04) although glucose 
concentrations were similar. Calculated indices of insulin resistance were also 
marginally higher in the young but did not achieve statistical significance whether 
assessed using QUICKI (0.38 ± 0.01 vs. 0.40 ± 0.01; young vs. older; P = 0.13) or 
HOMA-IR (1.18 ± 0.11 vs. 0.93 ± 0.16; young vs. older; P = 0.21).  
 
  Table 5.2   Characteristics of subjects. All values mean ± SEM; no significant difference 
(ns) between young and older participants when P > 0.05. 
 
 Young Older P 
n 8 8  
Age (y) 24.5 ± 1.8 65.0 ± 1.3 <0.0001 
M:F 4:4 4:4 ns 
Weight (kg) 71.1 ± 5.0 73.1 ± 3.3 ns 
Height (m) 1.7 ± 0.0 1.7 ± 0.0 ns 
CRP 2.1 ± 0.8 3.5 ± 1.3 ns 
BMI (kg.m-2) 23.9 ± 0.9 26.3 ± 0.4 0.03 
LBM (kg) 47.3 ± 4.4 45.8 ± 4.1 ns 
LBM.ht-1 (kg.m) 27.2 ± 1.8 27.3 ± 2.0 ns 
PA insulin  (µIU.ml-1) 6.0 ± 0.5 4.3 ± 0.5 0.04 
PA glucose (g.dl-1) 4.4 ± 0.1 4.8 ± 0.2 ns 
PA leucine  (µM.l-1) 113.2 ± 11.5  114.2 ± 8.2 ns 
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5.2.3 Clamp conditions 
Target conditions for the euglycaemic isoaminoacidaemic clamp studies were achieved 
for all participants. Insulin concentrations for the two study periods were 4.4 ± 0.6 and 
15.0 ± 0.7 µIU.ml-1 in the young and 3.3 ± 0.2 and 14.9 ± 0.4 µIU.ml-1 in older 
participants. Mean whole blood glucose across both periods was maintained at 4.7 ± 
0.1 and 4.8 ± 0.1 mmol.l-1 for young and older volunteers, respectively. Plasma insulin 
and glucose concentrations did not differ between the groups throughout the study 
(Figure 5.2).  
 
During the clamps, venous plasma leucine and total EAA concentrations rose above 
basal values, albeit not achieving statistical significance (Table 5.3). At each time point 
venous plasma concentrations were consistently higher in the older group than the 
young for leucine and EAA (both P < 0.01). Arterialized-venous leucine concentrations 
were also lower in the young (P < 0.02) but EAA did not differ significantly (Figures 5.3 
and 5.4). The CV for insulin, leucine and EA were all within 15 % of the mean. 
 
 
 
 
 
 
 
Table 5.3   Venous plasma concentrations of essential amino acid in young (Y) and older (O) healthy volunteers. All values in μmol.l-1 ± SEM; 
compared by student’s t-test (paired for within group and unpaired between group measurements). None of the differences between groups were 
significant. 
 
Young:  basal and at 5 and 15 µIU.ml-1 insulin Older: basal and at 5 and 15 µIU.ml-1 insulin 
Y vs. O 
Basal  
P 
Y vs.O 
5  
P 
Y vs.O 
15  
P 
Basal 5 15 
5 vs. 
15 
P 
Basal 5 15 
5 vs. 
15 
P 
Arg 74.2±5.0 104.6±7.4 123.7±10.8 0.26 110.9±33.2 130.4±31.5 152.9±31.1 0.02 0.30 0.41 0.37 
His 55.0±12.1 76.4±9.2 92.1±15.2 0.17 75.5±4.1 86.8±4.3 106.0±9.1 0.04 0.13 0.34 0.46 
Iso 50.3±4.0 58.4±4.2 57.1±5.4 0.86 53.0±3.5 64.3±2.8 68.2±5.7 0.47 0.59 0.27 0.18 
Leu 113.4±11.5 144.4±5.4 138.8±7.9 0.54 114.2±8.2 161.2±7.3 168.8±16.1 0.53 0.95 0.08 0.11 
Lys 135.5±17.1 170.5±17.2 201.2±26.0 0.16 177.8±13.4 208.7±13.4 243.4±24.6 0.05 0.06 0.11 0.26 
Met 27.4±3.1 29.6±2.9 46.6±7.4 0.04 28.9±3.3 35.0±3.4 49.6±5.2 0.01 0.74 0.25 0.75 
Phe 51.5±4.3 65.3±3.9 72.6±5.8 0.22 56.2±2.8 68.2±4.0 82.2±5.5 0.04 0.39 0.61 0.25 
Thr 116.8±12.1 130.4±9.9 140.9±10.7 0.30 113.6±4.6 128.8±7.0 139.5±6.4 0.20 0.81 0.91 0.91 
Try 58.5±10.9 52.1±2.7 52.7±3.5 0.83 62.34±4.0 60.42±4.0 64.4±4.9 0.35 0.75 0.10 0.07 
Val 199.8±11.7 210.4±7.1 219.6±13.7 0.51 208.7±13.1 234.0±11.4 248.7±22.5 0.40 0.62 0.09 0.28 
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Figure 5.2  Venous plasma insulin (left axis, solid line) and arterialized-venous whole 
blood glucose (right axis, dashed line) concentrations at baseline and during both 
pancreatic clamp periods for young (solid triangles) and older (open squares) 
participants. Mean ± SEM given, error bars not seen lie within symbols. 
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Figure 5.3  Plasma concentrations of venous and arterialized-venous leucine at 
baseline and during pancreatic clamping of insulin for young (closed triangles) and 
older (open squares) participants. All values mean ± SEM (error bars not seen lie 
within symbols), expressed in mmol.l-1. 
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Figure 5.4  Plasma concentrations of venous and arterialized-venous essential amino 
acids (EAA), at baseline and during pancreatic clamping of insulin for young (closed 
triangles) and older (open squares) participants. All values are mean ± SEM (error bars 
not seen lie within symbols), expressed in mmol.l-1. 
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5.2.4  Isotope enrichment  
Plasma enrichment of [1,213C2]α-ketoisocaproate (Figure 5.5) and D5 phenylalanine 
(Figure 5.6) were maintained at steady state throughout both periods for all 
participants.  
 
Figure 5.5  Atoms percent excess (APE) of [1,213C2] α-ketoisocaproate in plasma taken 
from venous blood of young (closed triangles) and older (open squares) participants, 
throughout the study. Mean ± SEM presented; error bars not seen lie within symbols. P 
> 0.05 ANOVA repeated measures within groups; P < 0.001 young vs. older. 
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Figure 5.6  Atoms percent excess (APE) of D5 Phenylalanine in plasma taken from 
venous blood of young (closed triangles) and older (open squares) participants, 
throughout the study. Mean ± SEM presented; error bars not seen lie within symbols. P 
> 0.05 ANOVA repeated measures; P < 0.001 young vs. older. 
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5.2.5 Femoral artery blood flow  
Femoral artery blood flow was greater in the young participants during both clamp 
periods. Increased insulin availability did not significantly alter blood flow in either group 
(Table 5.4).  
 
Table 5.4  Mean femoral artery blood flow. Given as ml per 100ml leg per min; mean ± 
SEM; young vs. older P < 0.05, within group analysis comparing insulin availability P > 
0.05; student’s t-test. 
 
 Young Older P 
~ 5 µIU.ml-1 insulin 3.64 ± 0.30 2.39 ± 0.20 0.01 
~ 15 µIU.ml-1 insulin 3.49 ± 0.33 2.56 ± 0.26 0.02 
P 0.15 0.25  
 
 
Chapter 5 
 180 
5.2.6 Phenylalanine and leucine kinetics 
Phenylalanine flux across the leg 
The phenylalanine balance differed with insulin availability significantly in the young but 
not the old (Figure 5.7). In the young, at 5 µIU.ml-1 insulin, phenylalanine balance was 
negative and significantly different from zero (or neutral balance) but at 15 µIU.ml-1 
insulin there was no difference from neutral phenylalanine balance. The older group did 
not differ from neutral balance at either insulin availability. An alternate version of this 
figure, accounting for the infused phenylalanine, is given in Appendix 7. 
 
Figure 5.7  Balance across the leg of unlabelled phenylalanine after pancreatic 
clamping at ~ 5 (open bars) and ~15 µIU.ml-1 insulin (hashed bars) for young and older 
healthy volunteers. Values are mean ± SEM; n = 8 both groups; the change in 
phenylalanine balance occurring with change in insulin availability was significant in the 
young (as indicated by the asterisk, P < 0.05 two-way ANOVA) but not the older 
participants.
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Whole body leucine flux 
Whole body leucine flux did not differ between participants of different ages or when 
studied under different insulin availability (Figure 5.8). 
 
 
  
 
Figure 5.8  Whole body leucine flux for young and older participants measured 
following pancreatic clamping at ~ 5 (open bars) and ~ 15 µIU.ml-1 insulin (hashed 
bars). Mean ± SEM; all P > 0.05 two-way ANOVA. 
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Leg protein breakdown 
Leg protein breakdown (LPB), whether determined by leucine or phenylalanine tracer 
dilution in whole blood, did not differ between the groups at PA insulin concentrations. 
At higher insulin availability, LPB was suppressed in the young participants by ~ 60 % 
(P < 0.05), whether measured using leucine or phenylalanine kinetics. In the older 
participants LPB was not significantly reduced with increased insulin (Figures 5.9 and 
5.10). 
 
 
Figure 5.9  Leg protein breakdown as determined by leucine flux across the leg at ~ 5 
(open bars) and ~ 15 µIU.ml-1 insulin (hashed bars) for young and older healthy 
volunteers. All values mean ± SEM. Significant change in the rate of leg protein 
breakdown, seen with higher insulin availability in the young, is marked by an asterisk 
(P < 0.05; two-way ANOVA).  
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Figure 5.10  Leg protein breakdown as determined by phenylalanine flux across the leg 
at ~ 5 (open bars) and ~15 µIU.ml-1 insulin (hashed bars) for young and older healthy 
volunteers. All values mean ± SEM. Significant change in rate of leg protein breakdown 
seen with higher insulin availability in the young is identified by the asterisk (P < 0.05; 
two-way ANOVA).  
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5.2.7 Muscle protein synthesis 
The rate of muscle protein synthesis, as determined by the incorporation of [1,2 13C2] 
leucine (Figure 5.11), did not change throughout the study for either group, nor was 
there a difference between data from young and older participants. Calculated rates of 
synthesis from phenylalanine flux did not differ from incorporation data (Figure 5.12). 
 
 
 
Figure 5.11  Fractional synthetic rate (FSR) of mixed muscle measured over 90 min at 
plasma insulin concentrations of ~ 5 (open bars) and ~ 15 µIU.ml-1 (hashed bars) for 
young and older healthy volunteers. All values mean ± SEM; all P > 0.05 two-way 
ANOVA. 
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Figure 5.12 Leg protein synthesis as determined by phenylalanine flux (rate of 
disappearance, Rd) across the leg at ~5 (open bars) and ~15 µIU.ml-1 insulin (hashed 
bars) for young and older healthy volunteers. All values mean ± SEM; all P > 0.05 two-
way ANOVA.  
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5.2.8 Activity of muscle signalling proteins 
In both young and older subjects, PKB activity fell with increased insulin availability 
(both P < 0.03; Figure 5.13). Phosphorylation status of eEF2, p70S6K, 4E-BP1 and 
FOXO1a did not change in either group at the time points sampled (Figures 5.14 – 
5.17).  
 
 
 
Figure 5.13  Protein kinase B activity relative to PKB recovery from immunoprecipitates 
for young and older healthy volunteers after 90 min pancreatic clamping at insulin 
concentrations of  ~ 5 (open bars) and ~ 15 (hashed bars) µIU.ml-1. All arbitrary units 
(AU), with mean ± SEM given; asterisk indicates the significant effect of insulin 
availability within each age group (P < 0.05; two-way ANOVA). No interaction exists 
between age and insulin availability. 
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Figure 5.14  Change in phosphorylation status of eEF2 relative to actin for young and 
older healthy volunteers following 90 min pancreatic clamping at insulin concentrations 
of  ~ 5 (open bars) and ~ 15 (hashed bars) µIU.ml-1. All arbitrary units, mean ± SEM; 
the effect of age, but not insulin availability, was significant (P < 0.05, two-way 
ANOVA). No interaction exists between age and insulin availability. Asterisk denotes 
significant difference from young data.  
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Figure 5.15  Change in phosphorylation status of p70S6K relative to actin for young 
and older healthy volunteers following 90 min pancreatic clamping at insulin 
concentrations of  ~ 5 (open bars) and ~ 15 (hashed bars) µIU.ml-1. All arbitrary units, 
mean ± SEM; all differences, including interation P > 0.05, two-way ANOVA.  
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Figure 5.16  Change in phosphorylation status 4E-BP1 relative to actin for young and 
older healthy volunteers following 90 min pancreatic clamping at insulin concentrations 
of  ~ 5 (open bars) and ~ 15 (hashed bars) µIU.ml-1. All arbitrary units, mean ± SEM; all 
differences, including interaction of age and insulin, P > 0.05, two-way ANOVA. 
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Figure 5.17  Change in phosphorylation status of FoxO1a  relative to actin for young 
and older healthy volunteers following 90 min pancreatic clamping at insulin 
concentrations of  ~ 5 (open bars) and ~ 15 (hashed bars) µIU.ml-1. All arbitrary units, 
mean ± SEM; all differences P > 0.05, including interaction, P < 0.05, two-way ANOVA.  
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5.2.9 Change in gene expression 
The change in expression of C2 proteosomal subunit, MuRF1, MAFbx, Cathepsin L 
and Ubiquitin mRNA in muscle tissue taken after 90 min exposure to plasma insulin 
concentrations of ~5 µIU.ml-1 insulin did not differ to that measured after exposure to 
~15  µIU.ml-1 insulin (Figures 5.18 and 5.19). GLUT4 mRNA expression increased with 
the higher concentration of insulin in both groups, albeit only reaching significance in 
the older group (Figure 5.20).  
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Figure 5.18  Fold change in expression of atrogene mRNA, specifically MAFBx and 
MuRF1, in young (open bars) and older (hashed bars) healthy volunteers after 90 min 
pancreatic clamped at insulin concentrations of ~15 compared with ~5 µIU.ml-1. Bars 
represent mean ± SEM; all P > 0.05 young vs. older Student’s t test. 
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Figure 5.19 Fold change in expression of Ubiquitin, C2 proteosomal subunit and 
Cathepsin L mRNA in young (open bars) and older (hashed bars) healthy volunteers 
following 90 min pancreatic clamped at insulin concentrations of ~15 compared with ~5 
µIU.ml-1. Bars represent mean ± SEM; all P > 0.05 young vs. older, Student’s t test. 
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Figure 5.20 Reduction in expression GLUT4 mRNA in young (open bars) and older 
(hashed bars) healthy volunteers after a 90 min period of higher insulin availability, 
where mRNA expression during the lower insulin clamp is normalized to 1.0. Bars 
represent mean ± SEM; a significant reduction from ~ 5 µIU.ml-1 clamp values occurs in 
the older group indicated by asterisk (P < 0.05 Student’s t test). No difference was 
seen between the groups. 
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5.3 Discussion 
These data demonstrate that ageing interferes with the normal suppression of LPB in 
response to a moderate rise in plasma insulin concentration. Under conditions of PA 
insulin availability, i.e. ~ 5 µIU.ml-1, there is no age differential in the control of leg 
protein turnover; whereas elevation of plasma insulin concentrations to ~ 15 µIU.ml-1 
(into the postprandial range) suppresses leg proteolysis in the young to a greater 
degree than in older healthy volunteers. 
 
5.3.1 Clamp conditions 
The data presented in this chapter cannot simply be explained by differences in body 
composition or insulin sensitivity as young and older healthy volunteers were not 
dissimilar. As in Chapter 4, the older participants had no evidence of pathological 
sarcopenia, although 2 of the older subjects had lost up to 1.5 kg LBM since 
participating in a previous program ~ 2 y earlier. Both groups had normal calculated 
values for insulin sensitivity ruling out the possibility of incipient diabetes contributing to 
impaired muscle metabolism.  Indeed basal insulin concentrations, HOMA-IR and 
QUICKI indices all suggest a greater degree of insulin sensitivity in the older group. 
Also, availability of free fatty acids, which have been shown to induce insulin resistance 
in skeletal muscle (Dresner et al. 1999), did not differ at any time point.  
 
Elevated plasma AA concentrations were seen in both the young and older volunteers 
over the 3 h study period, suggesting that infused AA were given excessively. Ideally 
real-time BCAA analysis would have been used alongside the glucose measurements 
in order to titrate the AA infusion to plasma concentrations; however development of a 
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real-time fluorometric assay, as used by others (Chevalier et al. 2004; Beckett 2000), 
was hampered by analytical problems. Thus best guess estimates were used in the 
development phase to establish a consistent protocol for later use. The main aim, to 
prevent hypoaminoacidaemia, was achieved for all participants and plasma AA 
concentrations did not increase sufficiently to elicit muscle protein synthesis.   
 
Venous plasma concentrations of individual EAA did not differ between young and 
older participants throughout the clamps; nevertheless half of the individual EAA 
concentrations rose in the second period in the older group, but not in the young. 
Impaired inhibition of MPB may be responsible, although it is feasible to suggest that 
hepatic deamination, which is diminished with ageing, is also culpable (Odeh-Ramadan 
& Remington 2002). Indeed other workers have also reported similar differences in 
plasma AA profiles with ageing (Rudman et al. 1989). Nevertheless increased AA 
availability is not thought to alter rates of MPB (Bennet et al. 1990b; Biolo et al. 1997; 
Volpi et al. 1999; Volpi et al. 2003). 
 
A second characteristic which differed between the groups was blood flow. The 
phenomenon of vasodilator blunting in response to insulin as a result of ageing has 
been recognized previously (Rasmussen et al. 2006; Meneilly et al. 1995) and may 
account for significantly lower blood flow seen in our older healthy volunteers. Other 
cardiovascular factors affecting blood flow, such as cardiac output and peripheral 
resistance, were not measured but are also likely to contribute. A dose dependent 
effect of insulin upon blood flow to the limb has been reported at insulin concentrations 
which exceed 45 µIU.ml-1 (Fujita et al. 2006; Biolo et al. 1999; Arfvidsson et al. 1991), 
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but not with moderate changes in insulin (Fujita et al. 2006) in keeping with the data 
presented here.    
 
5.3 2 Whole body and leg protein kinetics 
Other workers (Guillet et al. 2004b; Boirie et al. 2001) have measured whole body, but 
not muscle, leucine flux in response to different availabilities of insulin (up to 30 µIU.ml-
1). They have shown that protein breakdown is suppressed when plasma insulin is 
increased to absorptive concentrations in volunteers of all ages, but the degree of 
suppression is reduced in older human beings. However the whole body leucine flux 
data presented in this chapter did not confirm their findings: in the present data, whole 
body leucine flux did not differ with increasing insulin availability or between 
participants of different ages. 
 
These disparate findings may be accounted for by differences in body composition, as 
this differed markedly between studies, particularly for the younger participants. Mean 
values for BMI and proportion of fat mass were substantially lower in the work by Boirie 
and colleagues when compared with this data; thus the relative contribution of muscle 
protein turnover (rather than splanchnic protein turnover) to whole body flux is greater. 
The converse is true for less lean subjects. Consequently, suppression of MPB by 
insulin is offset by enhanced splanchnic proteolysis and whole body net balance 
remains unchanged. This differential effect of insulin on splanchnic and muscle tissue 
has been described previously, albeit not under isoaminoacidaemic conditions (Nygren 
& Nair 2003; Meek et al. 1998).  Thus, if the whole body work of Boirie and colleagues 
(Guillet et al. 2004b; Boirie et al. 2001) predominantly reflects changes in muscle 
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proteolysis in response to insulin, then their data corresponds well with that presented 
here.  
 
There are currently no other studies which assess the effect of postprandial insulin on 
the rate of leg or muscle proteolysis under isoaminoacidaemic conditions with ageing. 
Estimates of MPB in the PA state do not appear to differ with age  (Hasten et al. 2000; 
Volpi et al. 2000; Volpi et al. 2001; Yarasheski, Zachwieja, & Bier 1993) in keeping with 
the data presented here. In young adults, suppression of MPB appears dependent 
upon the dose of insulin, provided that isoaminoacidemia is maintained (Chow et al. 
2006; Moller-Loswick et al. 1994; Petrides, Luzi, & DeFronzo 1994; Louard et al. 1994; 
Arfvidsson et al. 1991; Fryburg et al. 1990; Flakoll et al. 1989; Gelfand & Barrett 1987; 
Tessari et al. 1986). Thus postabsorptive plasma AA concentrations were maintained 
throughout both phases of the study using a proprietary AA preparation, such that 
arterial EAA concentrations crept up slightly above basal values for both age groups 
towards the end of the study. Nevertheless, the rise in EAA availability was not 
sufficient to stimulate MPS, nor anabolic signalling protein phosphorylation, both of 
which remained at post absorptive values for both phases of the study. Furthermore, 
age did not affect rates of basal mixed MPS, in keeping with other published results 
(Volpi et al. 2001; Volpi et al. 2000; Katsanos et al. 2006; Yarasheski et al. 1999; 
Cuthbertson et al. 2005). Also, insulin has no effect upon MPS, beyond that of altering 
AA delivery to the tissues, as show by other workers (Greenhaff et al. 2008; Gelfand & 
Barrett 1987; Chow et al. 2006; Moller-Loswick et al. 1994) and confirmed by the 
current results.  
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Contradictory data published by Rasmussen et al. and Fujita et al. separately suggest 
that insulin can be infused directly into the femoral artery without eliciting a change in 
the rate of local MPB (Rasmussen et al. 2006; Fujita et al. 2006). Rasmussen et al. 
compared responses to local insulin infusions between young and older healthy 
volunteers in whom venous amino acid concentrations were maintained within 10 % of 
basal; however insulin concentrations within the femoral vein were doubled in the older 
group (40.3±1.0 vs. 83.4±6.2 µIU.ml-1; young vs. older, P < 0.05). When results from 
young volunteers with comparably high insulin concentrations are compared with the 
older group data there is a clear trend towards inhibition of proteolysis.  Fujita et al. 
present data which include a drop in the rate of appearance of phenylalanine at both 
low (~24%) and high insulin concentrations (~35%) albeit only reaching significance at 
the higher concentration, again confirming the presence of MPB suppression.  
 
5.3.3 Changes in phosphorylation of signalling proteins 
In terms of signalling proteins, PKB activity (not just phosphorylation status) which is 
frequently used as a proxy of insulin action (Adams et al. 2004), rose as expected with 
increased insulin availability. However, the presence of activated PKB should ordinarily 
inactivate FoxO1a (involved in muscle atrophy programmes) through phosphorylation 
and nuclear exclusion (Brunet et al. 1999), but this was not seen at the higher insulin 
availability.  The combination of no change in FoxO1a phosphorylation status and 
failure to detect down-regulation of atrogene mRNA expression reduces the likelihood 
of inhibition of MPB by the PKB-FoxO1a-atrogene axis.  
 
Both the anabolic sensing-signalling protein mTOR and the elongation factor eEF2, 
appear, at least in vitro, to be activated by insulin eEF2 (Redpath, Foulstone, & Proud 
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1996; Proud 2006) and are strongly implicated in the regulation of protein translation. 
However these data demonstrate that at low physiological insulin concentrations, 
despite PKB signalling, down-stream phosphorylation targets of mTOR and eEF2 
signalling are unaffected which may explain the lack of protein synthetic response to 
insulin. 
 
5.3.4 Significance and future research 
In real terms, the degree of insulinaemia achieved during the second period of this 
study (~15 µIU.ml-1) is comparable with that expected after a “healthy” low glycemic 
index meal, such as breakfast or a light lunch (Juntunen et al. 2002; Brand-Miller et al. 
2005), yet it would appear from these results that the normal suppression of proteolysis 
by insulin at this concentration is impaired with ageing. Whether this blunted sensitivity 
to insulin is also present at higher insulin concentrations, as may occur with meals 
containing refined carbohydrates, remains to be investigated. Nevertheless it appears 
that loss of muscle with ageing may be accelerated not only by a blunted anabolic 
response to AA but also relative insensitivity to the anti-proteolytic effects of insulin.  
Chapter 6  
General Discussion 
 
Chapter 6 
 203 
6.1 Discussion 
This thesis aimed to address a number of different hypotheses. Specifically:  
1. That daily administration of 200 mg thalidomide taken orally for 6 weeks is 
superior to placebo in terms of weight gain (both TBW and LBM) in patients with 
cachexia caused by oesophageal cancer and that it is well tolerated. 
2. That administration of insulin to achieve supraphysiological plasma 
concentrations overcomes anabolic blunting in older human beings when 
compared to their younger counterparts, both in terms of rates of muscle protein 
synthesis and phosphorylation of key intracellular signalling proteins in the 
mTOR pathway. 
3.  That the effect of a modest increase in blood insulin concentration upon 
suppression of leg protein breakdown (and key signalling proteins) is 
diminished in older healthy volunteers, when compared with young controls. 
 
The previous 3 chapters have presented data from a series of experiments conducted 
in vivo on healthy volunteers and patients with advanced oesophageal cancer, which 
aimed to test these hypotheses.  Unfortunately it was not possible to reject the null 
hypothesis in the study assessing thalidomide use in the oesophageal cancer (Chapter 
3), as too many participants were unable to complete the protocol due to ill-health 
and/or side-effects of the study drug. Nevertheless the trial demonstrated a high 
degree of toxicity in the patients studied, which was not expected from pilot work (Khan 
et al. 2003) which suggested 200 mg was both well tolerated and efficacious over a 2 w 
period.  Whether the same adverse event profile would have been seen with a smaller 
dose, or indeed whether a smaller dose would have a beneficial effect upon body 
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composition is unclear. However, patients allocated to receive placebo maintained their 
body weight, including lean tissue, against expectation, presumably as they maintained 
adequate nutrition.  Aggressive dietary and medical advice alone appears sufficient, or 
in the very least superior to thalidomide, to maintain body mass in end-stage 
oesophageal cancer.  
 
In sarcopenia, high dose insulin administration fails to overcome blunted intracellular 
anabolic signalling pathways in response to intravenous AA feeding in older healthy 
volunteers (Chapter 4). Blood AA concentrations were only modestly elevated, such 
that no difference could be detected between the FSR of young and older quadriceps 
muscle; however the phosphorylation of key intracellular proteins, specifically 4E-BP1, 
p70S6K, PKB and GSK3β in response to AA feeding was blunted in the young. This 
blunted signalling response suggests that excessive insulin availability is not sufficient 
to overcome anabolic blunting to AA in ageing. Nevertheless it does not disprove the 
idea that insulin resistance of protein metabolism underpins anabolic blunting. Indeed 
this may explain the lack of suppression of leg protein breakdown in older healthy 
volunteers induced by administering modest doses of insulin to simulate a light meal 
(Chapter 5); although no difference was seen between rates of leg protein breakdown 
in young and older healthy volunteers at basal insulin availability.  
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6.2 Further work 
It appears from the available literature and work presented in this thesis that 
physiological changes occur in skeletal muscle with healthy ageing and that the deficits 
are two-fold: both blunted anabolism and accelerated insulin-driven catabolism. A vast 
amount of work is still required to further elucidate the mechanism by which these 
processes occur, such that effective therapeutic agents can be developed. Specifically: 
1. Determining the time course of anabolic responses to AA and whether AA 
pharmacokinetics differ with ageing.  
2. Elucidating whether blunted suppression of protein breakdown with ageing 
occurs at higher insulin availabilities, such that occur following a high glycaemic 
index meal. It is plausible that “healthy” eating may be counterproductive in older 
human beings as higher insulin concentrations may be required to adequately 
suppress muscle catabolism. 
3. Exploring other pharmaceutical agents such as statins or melatonin. 
 
At present, the simple, safe and inexpensive intervention of adequate, regular dietary 
intake remains germane to both sarcopenia and cachexia.   
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Relevance to the Transplant Recipient. Annals of Transplantation. 10, 32-
35
  237 
  238 
  239 
 
  240 
Appendix 2   
WILKES EA, SELBY AL, ATHERTON PJ et al. (2009) Blunting of Insulin 
Inhibition of Proteolysis in Legs of Older Subjects May Contribute to Age-
Related Sarcopenia. Am.J Clin Nutr. 90, 1343-1350. 
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Appendix 3   
Karnofsky Performance Scale 
 
Taken from:  KARNOFSKY DA (1950) Nitrogen Mustards in the Treatment of Neoplastic 
Disease. Adv.Intern.Med. 4, 1-75. 
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100 % Normal no complaints; no evidence of disease 
90 % Able to carry on normal activity; minor signs or symptoms of disease 
80 % Normal activity with effort; some signs or symptoms of disease.  
70 % Cares for self; unable to carry on normal activity or to do active work 
60 % Requires occasional assistance, but is able to care for most of his personal 
needs 
50 % Requires considerable assistance and frequent medical care.  
40 % Disabled; requires special care and assistance 
30 % Severely disabled; hospital admission is indicated although death not imminent. 
20 % Very sick; hospital admission necessary; active supportive treatment necessary. 
10 % Moribund; fatal processes progressing rapidly 
0 % Dead 
 
Appendix 4  
Amino Acid constituents of Glamin 
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 Concentration (mg/ml) 
Dose infused over 
2.5 h (mg/kg) 
Alanine 16.0 34.0 
Arginine 11.3 24.0 
Asparginine 0 0 
Aspartic Acid 3.4 7.2 
Cysteine 0 0 
Glutamic acid 5.6 11.9 
Glutamine 20.0 42.5 
Glycine 11.21 23.8 
Histidine 6.8 14.5 
Isoleucine 5.6 11.9 
Leucine 7.9 16.8 
Lysine 9.0 19.1 
Methionine 5.6 11.9 
Phenylalanine 5.85 12.4 
Proline 6.8 14.5 
Serine 4.5 9.6 
Threonine 5.6 11.9 
Tryptophan 1.9 4.0 
Tyrosine 2.28 4.8 
Valine 7.3 15.5 
Total AA 136.6 290.3 
Total EAA 66.9 142.2 
Appendix 5  
Revised Piper Fatigue Scale 
 
Taken from: PIPER BF, DIBBLE SL, DODD MJ et al. (1998) The Revised Piper Fatigue Scale: 
Psychometric Evaluation in Women With Breast Cancer. Oncol.Nurs.Forum 25, 677-684. 
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Directions: For each of the following questions, circle the number that best describes the fatigue 
you are experiencing now. Please make every effort to answer each question to the best of your 
ability. Thank you very much.  
1. How long have you been feeling fatigue? (check one response only) 
a. Minutes___________ 
b. Hours_____________ 
c. Days______________ 
d. Weeks____________ 
e. Months___________ 
f. Other (please 
describe):_______________________________________________ 
 
2. To what degree is the fatigue you are feeling now causing you distress? 
No distress        A great deal of distress 
0 1 2 3 4 5 6 7 8 9 10 
 
3. To what degree is the fatigue you are feeling now interfering with your ability to 
complete your work or school activities? 
None                A great deal 
0 1 2 3 4 5 6 7 8 9 10 
 
4. To what degree is the fatigue you are feeling now interfering with your ability to visit or 
socialize with your friends? 
None                A great deal 
0 1 2 3 4 5 6 7 8 9 10 
 
5. To what degree is the fatigue you are feeling now interfering with your ability to engage 
in sexual activity? 
None                A great deal 
0 1 2 3 4 5 6 7 8 9 10 
 
6. Overall how much is the fatigue you are feeling now interfering with your ability to 
engage in the kind of activities you enjoy doing? 
None                    A great deal 
0 1 2 3 4 5 6 7 8 9 10 
 
7. How would you describe the degree of intensity or severity of the fatigue which you are 
experiencing now? 
Mild                         Severe 
0 1 2 3 4 5 6 7 8 9 10 
 
To what degree would you describe the fatigue which you are experiencing now as 
being: 
       8. Pleasant                 Unpleasant 
0 1 2 3 4 5 6 7 8 9 10 
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       9. Agreeable                          Disagreeable 
0 1 2 3 4 5 6 7 8 9 10 
       10. Protective                Destructive 
0 1 2 3 4 5 6 7 8 9 10 
       11. Positive                     Negative 
0 1 2 3 4 5 6 7 8 9 10 
       12. Normal                    Abnormal 
0 1 2 3 4 5 6 7 8 9 10 
 
13. To what degree are you now feeling:  
Strong                Weak 
0 1 2 3 4 5 6 7 8 9 10 
 
14. To what degree are you now feeling:  
Awake             Asleep 
0 1 2 3 4 5 6 7 8 9 10 
 
15. To what degree are you now feeling:  
Lively            Listless 
0 1 2 3 4 5 6 7 8 9 10 
 
16. To what degree are you now feeling:  
Refreshed               Tired 
0 1 2 3 4 5 6 7 8 9 10 
 
17. To what degree are you now feeling:  
Energetic                             Unenergetic 
0 1 2 3 4 5 6 7 8 9 10 
 
18. To what degree are you now feeling:  
Patient         Impatient 
0 1 2 3 4 5 6 7 8 9 10 
 
19. To what degree are you now feeling:  
Relaxed              Tense 
0 1 2 3 4 5 6 7 8 9 10 
 
20. To what degree are you now feeling:  
Exhilarated                  Depressed 
0 1 2 3 4 5 6 7 8 9 10 
 
21. To what degree are you now feeling:  
Able to concentrate              Unable to concentrate 
0 1 2 3 4 5 6 7 8 9 10 
 
22. To what degree are you now feeling:  
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Able to remember                Unable to remember 
0 1 2 3 4 5 6 7 8 9 10 
 
23. To what degree are you now feeling:  
Able to think clearly           Unable to think clearly 
0 1 2 3 4 5 6 7 8 9 10 
 
24. Overall, what do you believe is most directly contributing to or causing your fatigue? 
_____________________________________________________________________ 
 
25. Overall, the best thing you have found to relieve your fatigue 
is:____________________________________________________________________ 
 
26. Is there anything else you would like to add that would describe your fatigue better to 
us? 
_____________________________________________________________________ 
 
 
27. Are you experiencing any other symptoms right now? 
No 
Yes  Please describe__________________________________________________ 
_____________________________________________________________________ 
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Appendix 6 
APE of [1,213C2] α-KIC during Protocol 1     
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Atoms percent excess (APE) of [1,213C2] α-ketoisocaproate in plasma taken from 
venous blood of young (upper graph, closed triangles) and older (lower graph, open 
squares) subjects undergoing Protocol 1. Mean ± SEM presented. 
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Appendix 7  
Figure 5.7 modified to account for infused phenylalanine    
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Balance across the leg of unlabelled phenylalanine after pancreatic clamping at ~ 5 
(open bars) and ~15 µIU.ml-1 insulin (hashed bars) for young and older healthy 
volunteers, taking into account infused phenylalanine. Values are mean ± SEM; n = 8 
both groups; change in phenylalanine balance occurring with change in insulin 
availability did not differ significantly between insulin concentrations or age of 
participants (all P > 0.05 two-way ANOVA). 
 
